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Abstract

VIMENTIN OVEREXPRESSION CONTRIBUTES TO THE BIOLOGICAL
PROPERTIES OF METASTATIC HEAD AND NECK CANCER CELLS
Rachel Josephine Paccione
Master of Science
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University School of Medicine.
Virginia Commonwealth University, 2005
Major Director: W. Andrew Yeudall, Interim Director
Philips Institute of Oral and Craniofacial Molecular Biology, Biochemistry

Epithelial to mesenchymal transition occurs in the later stages of epithelial tumor
progression, with cells expressing mesenchymal markers. Of these, the intermediate
filament protein vimentin is frequently upregulated in metastatic carcinomas. Previously,
microarray studies showed that the gene encoding vimentin is highly upregulated in
metastatic HN12 cells compared to a related primary tumor cell line. In this study, we
confirmed this difference using real-time quantitative PCR, western blot analysis, and
irnmunostaining. Furthermore, EGF and TGF-P, growth factors that induce migration
and invasion of HN12 cells, produced synergistic increases in vimentin expression. To
assess the contribution of vimentin to the biological properties, HN12 cells were stably
transfected with a plasmid that directs synthesis of vimentin shRNA. Clones expressing

decreased amounts of vimentin were isolated and characterized. These cells showed
significantly reduced proliferation compared to non-targeting controls.

Moreover,

downregulation of vimentin led to a decrease in cell motility, as well as reducing their
ability to invade through a basement membrane substitute. Using transient transfection
assays, vimentin promoter activity was determined in HN12 cells to define regulatory
elements important for controlling vimentin upregulation in the absence or presence of
EGF and TGF-P. Taken together, the data indicate that overexpression of vimentin is
important for proliferation and invasion of metastatic HN12 cells, and suggest that EGFdependent pathways target binding elements in the proximal vimentin promoter, while
TGF-P is likely to act in an API-dependent manner. Furthermore, both growth factors
appear to synergize by stimulating promoter activation through the ASE site, suggesting
involvement of Stat-dependent pathways in regulation of vimentin expression in HN12
cells.

1. Introduction

1.1. Growth Control and Tumor Development
Cancer is caused by the failure of regulatory mechanisms that control the growth
and survival of cells. During normal development, intricate genetic control systems
regulate the balance between cell proliferation and cell death in response to growth
promoting signals, growth-inhibitory signals, and death signals. The growth of tumor
cells depends not only on the increase of cells that are proceeding through cell division,
but also a decrease in the number of cells that are undergoing programmed cell death
(Martin, 1996). Programmed cell death or apoptosis is a physiological process that
embodies a series of characteristics and genetically controlled steps, which include
chromatin condensation and fragmentation, cell shrinkage, and the engulfment of the cell
by neighboring cells without an inflammatory response (Martin, 1996). Apoptosis is
essential for both normal development and tissue homeostasis in the adult (Stellar, 1995).
It is the failure of certain tumor cells to undergo apoptosis that appears to be one of the
factors underlying the genetic instability of these particular cells, their resistance to
chemotheurapeutic agents, and their increase in proliferation (Martin, 1996).
The loss of cellular regulation contributes to the genesis of malignancies and is
due in large part to genetic damage. Genetic changes in proto-oncogenes and tumor
suppressor genes are primarily responsible for the initiation and progression of a tumor

(Martin, 1996).

Since the majority of mutations do not increase the growth

characteristics of a cell, specific genetic changes must underlie the progression to cancer
(Lowy, 1996). For instance, proto-oncogenes may be activated to become oncogenes by
a particular mutation, which causes the gene to become excessively active in growth
promotion, or they may bc expressed inappropriately. In addition, tumor suppressor
genes that normally restrain the growth of cells can be inactivated, thereby de-regulating
cell growth.
Proto-oncogenes are appropriately named because they are essentially progenitors
of oncogenes or precursors of cancer genes. Proto-oncogenes can be converted into
oncogenes by several mechanisms, including intragenic mutation and chromosomal
rearrangement (Bishop and Hanafusa, 1996). In either case, the result is the abnormal
uninhibited expression of a gene or the deregulation of the protein product (Bishop and
Hanafusa, 1996). Proto-oncogene products participate in cell signaling that drives cell
growth and usually falls into one of four categories: growth factors, growth factor
receptors, intracellular signal transducers, and transcription factors (Leis and Livingston,
1996). Oncogenes may be associated with a cancer predisposition as a result of a
mutational event in many types of cancers, they may gain function through a dominant
allele in which only one allele is mutated in cancer, and are rarely passed on to progeny
through germ line transmission (Leis and Livingston, 1996). On the other hand, tumor
suppressor genes are negative regulators of cell growth that undergo loss of function
through mutation of both alleles, although for some genes, loss of a single allele is
enough to perturb suppressor function (haploinsufficiency). Germ line transmission of a

mutant allele results in predisposition to developing malignant disease (Leis and
Livingston, 1996).
As noted previously, oncogenic mutations usually only occur in somatic cells;
therefore, the mutations are not passed from one generation to another. In order for
oncogenic mutations to induce cancer, the mutations must occur in the dividing cells and
therefore be passed to progeny cells. When such a mutation occurs in nondividing cells,
e.g. neurons or muscle cells, the mutation generally does not induce cancer, which is one

reason why tumors of muscle and nerve cells are very rare in adults.
However, there are certain inherited mutations in tumor suppressor genes, for
example mutations in RB and BRCAI, which are carried through the germ-line and
increase the probability that cancer will occur during an individual's lifetime (Leis and
Livingston, 1996). Mutations in the proto-typical tumor suppressor genes generally
behave in a recessive manner at the molecular level and therefore it is only when both
copies of the gene become inactivated that an abnormal phenotype will manifest in the
cell (Leis and Livingston, 1996). It is due to this recessive genetic behavior that a single
mutant allele of such a gene can be passed through the germ line which is tolerated
during embryogenesis because its presence is revealed in a tissue only when the
remaining wild-type allele is lost (Leis and Livingston, 1996).
Oncogenic mutation or loss of tumor suppressor function may result in cancer
cells acquiring a proliferative potential that does not necessarily require an external
inducing signal. In addition, these cells may fail to sense particular signals that restrict
cell division and continue to grow within the tissue when they should otherwise

differentiate or die. Furthermore, cancer cells often alter their attachment to adjacent
cells and to extracellular matrix in order to gain the potential to migrate and invade into
surrounding tissues.
Tumor cells must develop a blood supply in order to survive in the tissue, a
process known 2s angiogenesis.

Angiogenesis is a complex phenomerion ,of

neovascularization that facilitates provision of nutrients to sustain the continued growth
and survival of tumor cells. Without this, tumor growth would be severely limited.
Angiogenesis requires several discrete steps; degradation of the basal lamina surrounding
a nearby capillary, migration of endothelial cells lining the capillary into the tumor,
endothelial cell division, and the formation of a new basement membrane around the
newly elongated capillary. During the early stages of cancer, an abundant amount of new
capillaries usually exists along the basement membrane below the transformed epithelium
(Weinberg and Hanahan, 1996). However, if neovascularization persists in an invasive
cancer, then the capillaries have the ability to breach the basement membrane and invade
through the stroma (Weinberg and Hanahan, 1996). Interestingly, it is thought that
transforming growth factor

P

(TGF-P) may play an important role in angiogenesis

because along with other angiogenic factors, cells release TGF-P during development and
tissue repair as part of a mechanism that promotes the vascularization of normal tissues
(Weinberg and Hanahan, 1996).
The majority of benign tumors pose little risk to the host because they remain
localized and are small. The cells that compose a benign tumor resemble and may even
function like normal cells while maintaining cell adhesion and thereby restricting the

tumor to the site of origin. In contrast, malignant tumor cells have the capability of
dividing rapidly compared to normal cells, as well as enhanced survival. Thus, malignant
cells usually exhibit the characteristics of rapidly growing cells, that is, high nucleus-tocytoplasm ratio, prominent nucleoli, and relatively little specialized structure. The major
characteristics that differentiate malignant tumors from benign lesions are their
invasiveness and ability to spread to local, regional and distant body sites.

1.2. Metastasis
Metastasis occurs when a tumor invades into the surrounding tissue, gets into the
circulatory or lymphatic systems, allowing the cells to spread to regional or distant sites
and facilitating the establishment of secondary foci of proliferation. Invasion of the
underlying connective tissue proceeds in stages and is mediated by various factors
produced by the tumor cell (Weinberg and Hanahan, 1996). For metastasis to occur,
tumor cells must release proteases such as collagenase IV, which dissolves the collagen
in the basement membrane allowing the tumor to penetrate the subjacent stroma. These
invasive cancers express membrane-localized receptors for laminin and fibronectin,
which are large glycoprotein components of the basement membrane and connective
tissue stroma, respectively. It is the binding of these elements that provides the tumor
cells with a lattice for anchorage and attachment.

Enzymes such as plasminogen

activators, collagenases I, cathepsins, heparanase, and hyaluronidase are released by the
tumor cells and destroy the matrix constituents, thereby enabling the cells to advance
further into the connective tissue (Weinberg and Hanahan, 1996).

However, fewer than 1 in 10,000 cells that escape from the primary tumor site
survive to colonize another tissue and form a secondary, metastatic tumor. In the case of
hematogenous spread, cells that escape the primary tumor must adhere to the endothelial
lining of a capillary and migrate across or through it to the underlying tissue in order to
enter circulation. In addition, tumor cells secrete autocrine motility factors.that direct
their migration, as well as vascular permeability factors that allow plasma proteins to
accumulate in the tumor and angiogenic factors that increase the vascularity of the tumor
(Weinberg and Hanahan, 1996).
As the tumor develops, the cells become very well adapted to growth and invasion
of the surrounding tissues. The invasion of tissues is nonrandom, depending on the nature
of both the metastasizing cell and the invaded tissue. It is thought that the tumor cells
preferentially invade along the pathways that provide the least resistance, such as the
connective tissue stroma (Weinberg and Hanahan, 1996).
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Figure 1: Sequential steps of the metastatic cascade. The process of metastasis
begins when an individual tumor cells detaches from the primary tumor. The
progression to metstasis requires individual tumor cells adhering and invading
through the basement membrane, migrating through extracellular matrix, and
intravasating into blood or lymphatic vessels, where the tumor cells can
disseminate to distant sites. In addition, the tumor cells must extravasate out of
the vessel and invade into the target organ, which forms a metastatic tumor.
(Howell and Grandis, 2005)

1.3. Head and Neck Cancer
Squamous cell carcinoma of the head and neck region (HNSCC) is the sixth most
common malignancy worldwide, representing 6% of all cancers.

Each year

approximately 40,000 individuals in the United States are diagnosed with HNSCC (Kim
and Califano, 2004) and more than two-thirds of these cases will present with advanced
stages (stage I11 and IV) (AJCC, 1983). The 5-year survival rate has remained largely

unchanged over the last two decades at 50% despite the significant improvements in the
treatment of this disease that has decreased morbidity (Kim and Califano, 2004). Studies
have shown that if the patient survives the initial lesion, a constant and continuing risk
(from 2.7-4% per year) of secondary primary tumor formation exists following the initial
treatment (Jovanovich et al., 1994). The probability of a second malignancy forming
within five years after the presentation of the initial tumor may be as high as 22%
(Dhooge et al., 1998).
Head and neck squarnous cell carcinoma (HNSCC) is a locally aggressive
malignancy that may develop after years of prolonged abuse of alcohol and tobacco
products. Exposure to these particular agents results in alterations in genes that are
important for the regulation of various cellular functions, which allows tumor cells to
survive and grow in an uninhibited manner, as discussed above (section 1.1). Some of
these important functions include the acquisition of immortality, the ability to invade
tissue andlor metastasize to other sites, and acquiring the ability to induce angiogenesis
(Hasina and Lingen, 2001).
HNSCC

generally

responds

inadequately

to

chemotherapeutic

and

radiotherapeutic measures; therefore, surgery remains the primary treatment. However,
patients with locally advanced, operable (HNSCC) are known to be at high risk of
treatment failure, which ranges from local regrowth to lymphatic spread and systemic
dissemination (Bernier and Cooper, 2005). HNSCC lesions are locally aggressive and
frequently metastasize to local and regional lymph nodes.

Therefore, treatment of

HNSCC must address not only the initial primary lesion, but also early diagnosis of high-

risk pre-malignant lesions to prevent malignant development and progression. Poor longterm survival is due to numerous variables including delayed diagnosis as well as the
development of multiple primary and secondary tumors. Thus, in addition to early
detection, continued emphasis must be placed on preventing the development of
secondary tumors as well a? establishing more effective treatments for individuals who
present with advanced disease.

1.4. Intermediate Filaments and Cancer
The intermediate filament protein family consists of at least 65 distinct proteins,
in which all assemble into 10 nm wide filaments and serve as prominent structural
elements both in the nucleus and the cytoplasm (Herrmann and Aebi, 2004). The family
comprises both nuclear (lamins) and cytoskeletal proteins such as cytokeratins, vimentin,
desmin, glial fibrillary acidic protein, neurofilaments, internexin, nestin, and peripherin
(Steinert and Leim, 1990). Two other principal structural elements of the eukaryotic cell
cytoskeleton are microtubules and microfilaments. Compared to both microtubules and
rnicrofilarnents, which often break when subjected to shear stress, intermediate filaments
become viscoelastic and are flexible (Janmey et al, 1998). The molecular building blocks
of intermediate filaments are fibrous proteins that consist of long, uninterrupted segments
of a-helices. Since single a-helical chains are unstable in aqueous solution, they often
adopt a rope-like structure by forming multistranded left-handed coiled coils (Watson and
Crick, 1953). With the use of electron microscopy, it has been shown that coiled-coil
intermediate filaments protein dimers are 45 to 50 nm long rod-like molecules.

Intermediate filament proteins may be useful for the diagnosis of certain tumors
because of their distinct expression patterns. For example, in some malignant tumors the
cells lose their normal appearance and, therefore, their origin is unable to be identified
purely on morphological grounds. However, the expression of particular intermediate
filament proteins is one of the differentiated properties of the cell that may be retained in
tumor cells. Hence, with the use of antibodies specific for the intermediate filament
protein of interest, researchers can determine exactly where the tumor originated,
epithelial, mesenchymal, or neuronal tissue. Identifying the intermediate filament protein
in a tumor cells may allow physicians to select the most effective treatment because
epithelial and mesenchymal malignancies may be sensitive to different therapeutic
regimes.

1.4.1. Vimentin
The fact that intermediate filaments span from the nucleus to the cell membrane
suggests that intermediate filaments have the potential to play significant roles in the
structural stability of the cell and the ability to transmit andlor transduce mechanical
signals into biological responses (Coulombe et al., 2000). Vimentin, which is a major
structural component of intermediate filaments in many different cell types, has been
shown to play a significant role in essential mechanical and biological functions
including cell contractility, migration, and proliferation (Wang and Starnenovic, 2002).
Live imaging of cells expressing the GFP-vimentin fusion protein revealed that
the vimentin network is motile, with the filaments constantly changing the shape of the

cell (Yoon et al., 1998; Helfand et al., 2002). It is the motile properties of vimentin
filaments that are particularly evident in the spreading cell, in which three different
structural forms of vimentin are involved in the assembly of the vimentin network
(Prahlad et al., 1998).

Figure 2: GFP-vimentin in a living endothelial cell. (Helmke et al., 2000)

1.4.2. Vimentin and Epithelial to Mesenchymal Transition
Vimentin serves as an appropriate marker for EMT because it is an established
marker for the mesenchymal cell and is not normally expressed in cells of epithelial
origin. EMT is one feature that may characterize the progression of a tumor toward a
highly malignant phenotype, and involves numerous changes in gene expression that
result in the substitution of epithelial characteristics for those of the mesenchymal cell
(Gilles and Thompson, 1996). Typically, cells that have undergone EMT exhibit a
spindle-shaped morphology with organized cytoskeleton, reduced cellular adhesions, and

the expression of specific mesenchymal cell markers such as vimentin. This correlation
between EMT and increased vimentin expression has been shown in a variety of tumor
cells, including invasive breast cancer cells (Korsching et al., 2005) and liver metastasis
of a pancreatic carcinoma (Nakajima et al., 2004). In addition, it has been shown that
many growth factors and cytokines induce EMT (Boyer et al., 2000; Thiery, 2002).

1.4.3. Cytokeratin and Epithelial to Mesenchvmal Transition
Whereas vimentin is turned on during EMT, a normal epithelial specific
intermediate filament, cytokeratin, is downregulated andlor switched to a different
isoform (Wu et al., 2003). In vivo studies and experimental models show that epithelial
cells are polarized, display cytokeratin filaments and membrane-associated specialized
junctions such as demosomes and adherens junctions (Hay, 1995; Savagner et al., 1994).
It is after EMT when these epithelial features are lost and the acquisition of mesenchymal
characteristics occurs, which includes vimentin filaments and a flattened phenotype (Hay,
1995; Savagner et al., 1994). Therefore, cytokeratins are highly regulated during EMT
and progressively vanish from within the cell when the vimentin level inside the cells
increases and adopts a mesenchymal phenotype (Boyer et al., 1989).
It has been proposed that EMT represents a permanent switch from cytokeratin to
vimentin in certain tumors (Gilles et al., 1997), consistent with the findings of an
androgen-independent model of prostate cancer which demonstrated an increase in
vimentin expression of the metastatic cell line accompanied by a decrease in the levels of
cytokeratin (Singh et al., 2003) as well as mammary epithelial cells that underwent EMT

in response to transfection with the matrix metalloproteinase stromelysin 1 (Lochter et
al., 1997).
EMT
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Figure 3: In vitro EMT in carcinoma cells. After EMT, the cells express
mesenchymal cell markers such as vimentin, become individualized, spread, and
migrate. (Savagner, 200 1)

1.4.4 Vimentin Gene Expression
Vimentin expression is upregulated in some metastatic tumor cells, making it a
potential marker of oncogenic progression. The promoter of the vimentin gene contains
multiple elements responsible for its complex transcriptional regulation, including a
TATA-box, several positive regulatory elements that include eight GC-boxes (Rittling
and Baserga, 1987), a PEA3 site (Chen et al., 1996), an NF-KB site (Lilienbaum and
Paulin, 1993), A19 site (Salvetti et al., 1993), a PS element (Wieczorek et al., 2000), two
tandem AP-1 binding sites (Rittling et al., 1989), a 0-catenin site (Gilles et al., 2003), an
antisilencer (ASE) element (Izmailova and Zehner, 1999), and a proximal silencer
element (Salvetti et al., 1993). Determining what controls vimentin expression could

lead to an understanding of what contributes to the changes in gene expression that
occurs during transformation to the malignant state.

-800

-600

APl APl
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Figure 4: A diagram of the relative position of vimentin's previously reported
regulatory elements; Gc-box 1, PEA3, NF-KB, PS, H4TF-1, tandem AP- 1 binding
sites, and ASE.

1.5. Growth Factors
Growth factors interact with specific protein receptors at the cell surface, which
are generally proteins that traverse the lipid bilayer of the plasma membrane. The growth
factor receptors contain an external ligand-binding domain and a cytoplasmic domain,
which triggers further biochemical events within the cell. The term "signal transduction"
is used to characterize this process in which binding of the growth factor leads to the
activation of specific intracellular pathways. The activated receptor induces a change at
the cytoplasmic side of the membrane by either becoming enzymatically active or by
interacting with other regulator proteins at the plasma membrane. This leads to a series
of events in the cytoplasm; for example, changes in ion concentration, production of
second-messengers, or activation of protein kinases, which are the enzymes that

phosphorylate other protein substrates. These cytoplasmic signals can then alter gene
expression within the nucleus. (Bishop and Weinberg, 1996)

In normal tissue, adjacent cells or distant cells that have the ability to produce and
release growth factors control the amount of growth factor available to the cell, which
ensures normal levels of proliferation. However, certain cells have the ability to undergo
autocrine stimulation in which they have the capability of expressing both the growth
factor and the receptor. Therefore, once the growth factor is secreted it can be considered
to be constantly in the active state because subsequent binding of the growth factor to the
receptor stimulates a cellular response. Therefore, normal regulatory events that prevent
prolonged interaction of the growth factor and its receptor are bypassed, thereby
contributing to cellular transformation. (Pawson, 1996)

1.6. Transforming Growth Factor-Beta

1.6.1. Introduction to Transforming Growth Factor-Beta
The mammalian transforming growth factor-beta (TGF-P) family consists of five
isoforms: TGF-PI, TGFP-2, TGFP-3, TGFP-4 and TGFP-5.

All are secreted and

activated in the extracellular environment and bind to receptors at the cell surface
receptors, of which there are three types: TGF-PI, TGF-PII, and TGF-PIII. The TGF-P
isoforms share 64-82% similarity at the amino acid level, largely due to a conserved
cysteine knot structure that is characteristic of the TGF-P monomer (Archer et al., 1993;
Daopin et al., 1992; Schlunegger and Grutter, 1992). Interestingly, the type I11 receptor

is also known as a betaglycan and can exist in a soluble form that has the ability to bind
two TGF-P molecules (Bachman and Park, 2005). Therefore, it is this increased binding
capacity which allows a greater concentration of TGF-P molecules to be present at the
cell surface, thus maximizing the interaction of TGF-P with type I and type I1 receptors
(Lopez-Castillas, et al., 1993) which transduce the signal to the intracellular environment.
Recent advances in molecular biology reveal that tumor development requires the
accumulation of a particular set of cellular characteristics. These include the ability to
grow independently of exogenous growth factors, to divide indefinitely, to grow new
blood vessels, and to invade surrounding tissues. The TGF-P signaling pathway regulates
many of these cellular processes, and tumor cells may exploit alterations in TGF-P
signaling cascade to promote malignant progression (Rich et al., 2001).

1.6.2. TGF-8 - Tumor Suppressor or Tumor Promoter?

Normal

Benign

Malignant

Metastatic

TGF-p overexpression

Figure 5: Model of TGF-P action in cancer.

TGF-P is a cytokine that is known for its ability to inhibit epithelial proliferation.
However, many epithelial malignancies acquire a resistance to the growth-inhibitory

effects of TGF-P. Therefore, it is thought that this resistance is part of a particular
signaling event is which TGF-P loses its growth inhibitory effects and is then used by the
epithelial cells to promote cell growth (Bachman and Park, 2005).
It is important to note that in some model systems, mutated TGF-P receptors
appear to block TGF-P signaling completely because neither growth-inhibitory nor
growth-promoting responses are observed (Bachman and Park, 2005). Therefore, it is
thought that the decision of the cancer cell to use TGF-P as a tumor suppressor instead of
as a tumor promoter is not mediated at the level of the ligandlreceptor interaction.
Over the last decade, numerous studies have demonstrated that TGF-P1 not only
maintains transforming potential but can also drive malignant progression, invasion and
metastasis both in vitro and in vivo (Derynck et aL., 2001). It has now become clear that
TGF-P can act as both a tumor suppressor in which three isoforms bind to the same type
I1 receptor (Akhurst and Derynck, 2001) and as a significant stimulator of tumor
progression, invasion, and metastasis (Cui et al., 1996).
At the early stages of tumorigenesis when the lesion is still benign, TGF-P acts
directly on the cancer cells to suppress tumor growth. However, as the tumor progresses,
genetic and/or biochemical changes allow the TGF-P to stimulate tumor progression on
both the cancer cell and on the non-malignant stromal cell types on the tumor (Akhurst
and Derynck, 2001). It is this stimulation and metastasis caused by TGF-P that might be
of greater clinical significance because a majority of tumors retain the functional TGF-P
signaling pathway.

1.6.3. TGF-B Signaling Pathway in Tumor Progression
Two general mechanisms may explain the contribution of TGF-P signaling to
enhance tumor progression, invasion, and metastasis. First, there can be an early loss of
signaling components, such as the type I1 TGF-P receptor, leading to rapid tumor cell
growth. It is this increased cell division that also potentiates the probability of further
cancer-causing mutations and cytogenetic changes that have the ability to drive tumor
progression.

Second, the TGF-P signaling pathway can remain intact, but become

disrupted by other mechanisms such as deregulated Smad signaling. The altered Smad
signaling leads to a direct increase in tumor cell plasticity, invasion, and metastasis.
(Akhurst and Derynck, 2001)

1.6.4. TGF-I3 and Smad Signaling
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Figure 6: General mechanism of TGF-/3 receptor and Smad activation.

TGF-P is secreted from cells as a biologically inactive latent form that requires
some processing to generate the active growth factor. At the cell surface, TGF-P binds to
a complex of transmembrane receptor serineltheorine kinases (type I and 11) and induces
the phosphorylation of the GS segment on the type I receptor by the type I1 kinases. This
heterodimeric transmembrane receptor complex is composed of type I1 (TPRII) and type

I receptors (AlkSlTPRI) (Glick, 2004). The type I1 receptor is a constitutive kinase and
capable of binding TGF-P1 on its own (Glick, 2004). However, the type I receptor

kinase is only activated after complex formation and trans-phosphorylation by the type I1
receptor (Glick, 2004).
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ALK-2

Smadl
Smad5

Table 1: Combinatorial interactions of type I1 and type I receptors define the
signaling responses.

The activated type I receptor phosphorylates selected Smad proteins at serine
residues within the C-terminal region. These receptor-activated Smads (R-Smads) then
form a complex with Smad4 (Derynck and Zhang, 2003). Smad2 and Smad3 are the
major substrates for the activated type I kinase (Glick, 2004). These proteins are inactive
cytoplasmic transcription factors until they become phosphorylated by the ligand-bound
receptor complex, at which point they bind to Smad4 and translocate to the nucleus
(Glick, 2004). R-Smads and Smad4 shuttle back and forth between the nucleus and
cytoplasm (Derynck and Zhang, 2003).
Upon translocating to the nucleus, Smad complexes regulate transcription of
target genes through physical interaction and functional cooperation with DNA-binding

factors or coactivators such as CREB-binding protein (CBP) and p300 (Derynck and
Zhang, 2003).

Positive and negative regulation of transcription occurs with the

cooperation of other DNA binding proteins and transcription factors at both the Smad
binding elements (SBE) in the promoter regions of target genes and at the binding sites
for other transcription factors (Derynck and Zhang, 2003).
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Figure 7: R-Smad activation is regulated by receptor interacting proteins and
Smad617.

Interestingly, activation of R-Smads by type I receptor kinases is inhibited by
Smad6 or Smad7 (Derynck and Zhang, 2003).

In contrast to R-Smad expression,

expression of the inhibitory Smad6 or Smad7 is highly regulated by extracellular signals
(Derynck and Zhang, 2003). Induction of Smad6 and Smad7 expression by BMP and

TGF-P respectively represents an auto-inhibitory feedback mechanism for ligand-induced
signaling (Massague et al., 2000; Itoh et al., 2000; Moustakas et al., 2001). Activation of

EGF receptor and possibly other tyrosine kinase receptors, interferon-y (INF-)I) signaling
through Stat (signal transducer and activator of transcription) proteins, and activation of

NF-KB by tumor-necrosis factor-a (TNF-a), also induce Smad7 expression, which leads
to inhibition of TGF-P signaling (Massague et al., 2000; Itoh et al., 2000; Moustakas et
al., 2001).

1.6.5. TGF-$ signaling through Smad Independent Pathways
Other proteins can associate with type I or type I1 receptors and regulate TGF-P
ligand signaling without the direct effect of Smad activation. The activated receptor
complexes activate non-Smad signaling pathways, such as TAKlNEKK-1, Ras, RhoA,

PP2A signaling pathways (Derynck and Zhang, 2003).

1.6.6. TGF-8 and EMT
TGF-P1 is a ubiquitous cytokine that was originally named for its ability to
transform normal fibroblasts in culture. Subsequently, TGF-PI was found to inhibit
growth of normal epithelial cells, although it was also discovered that TGF-P1 could
induce tumor cells to proliferate and promote an invasive phenotype and the ability to
metastasize by mediating changes in the cytoskeletal architecture, which is known as
EMT (Massague et al., 2000). Autocrine TGF-fl expression by tumorgenic cells induces
matrix degradation, downregulates basement membrane components, and cell-cell
adhesion molecules; such as E-cadherin, and induces an invasive, motile phenotype
(Glick, 2004).

It has been shown that TGF-P can induce morphological changes characteristic of
EMT in normal and transformed mammary epithelial cells in culture (Oft et al., 1996;
Miettinen et al., 1994). Furthermore, these experiments have also shown that this
cytoskeletal reorganization is accompanied by the downregulation of adhesion and
cytoskeletal proteins. such as E-cadherin and keratins, and induce de novo expression of
the mesenchymal intermediate filament protein, vimentin (Oft et al., 1996; Miettinen et
al., 1994). Since these initial experiments, TGF-P-induced EMT has also been reported

in epidermal squamous cell carcinoma (Portella et al, 1998), in ras-transformed
mammary carcinoma cells (Oft et al., 1996) and in ovarian adenosarcoma cells (Kitagawa
et al., 1996).

1.6.7. TGF-B Stimulates Angiogenesis
As mentioned earlier (section 1.1), tumor angiogenesis is critical for tumor
growth and invasion because this process facilitates the delivery of nutrients and oxygen
to the tumor cells allowing sustained, rapid growth. The mechanism of angiogenesis
simulation by TGF-PI is a combination of direct and indirect effects. Directly, TGF-P
induces the expression of angiogenesis-inducing vascular endothelial cell growth factor
(VEGF) (Pertovaara et al., 1994). TGF-P also can directly induce capillary formation of
the endothelial cells cultured on a collagen matrix (Madri et al, 1998). Indirectly, TGF-P
induces expression of the metalloproteases MMP-2 and MMP-9, as well as
downregulation of tissue inhibitor metalloproteases (TIMPs) in tumor and endothelial

cells, thus providing a protease-rich microenvironment that is conducive to the enhanced
migration and invasion of active endothelial cells (Hagedorn et al., 2001).

1.6. Epidermal Growth Factor

1.6.1. Epidermal Growth Factor Introduction
Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that is
overexpressed in a number of human epithelial malignancies, including carcinomas of the
lung, colon, ovary, bladder, and head and neck (Bishop and Weinberg, 1996). EGFR
stimulates several properties that are critical for tumor progression, including
proliferation, cell motility, cell adhesion, invasion, cell survival, and angiogenesis
(Grandis and Sok, 2004).
EGFR is a 170-kDa plasma membrane glycoprotein containing an extracellular
ligand-binding domain, a single transmembrane domain, an intracellular domain with
intrinsic tyrosine activity, and a C-terminal tail that contains specific tyrosine containing
sequences that become binding sites for SHZcontaining signaling proteins upon
phosphorylation. EGFR is one of a family of four structurally similar receptors that make
up the erbB family. These receptors show homology in their kinase domains but are
different in their extracellular regions and C-terminal tails. The erbB family of receptors
are widely expressed in a variety of tissues and regulate different functions, including
mitogenesis, differentiation, and cell survival and can undergo homo- (thick arrows) or
heterodimerization (thin arrows) both constitutively and in response to the presence of

specific ligands resulting in the potential to activate many signaling pathways (Grandis
and Sok, 2004).
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Figure 8: EGFR Signaling Pathway.

Specificity of signaling is generated, at least in part, through the range of ligands
and the intracellular protein-protein interactions that occur downstream of these erbB
receptors. The selective activation of the signaling transduction pathways (yellow boxes)
depends on the various arrangements of the ligand-erbB engagement, tyrosine

phosphorylation, and subsequent receptor dimerization combinations beneath the cell
surface (Grandis and Sok, 2004). In addition, for example, several ligands bind to
EGFRIerbBl, including epidermal growth factor (EGF), transforming growth factoralpha (TGF-a), and amphiregulin (Grandis and Sok, 2004).

1.7.2. Epidermal Growth Factor and Head and Neck Cancer
The up-regulation of EGFR expression and activity has been described in a
number of epithelial tumors, including HNSCC (Howell and Grandis, 2005). 80-100% of
head and neck tumors express EGFR (Grandis et al., 1998). Furthermore, EGFRIerbBl,
erbB2, and erbB3 have each been independently correlated with the presence of nodal
metastases and a shortened length of survival (Do et al., 2004; Xia et al., 1999). Studies
have provided support for the prominent role of EGFR in controlling HNSCC invasion
and metastasis and indicate EGFR as being one of the strongest predictors of survival and
locoregional relapse (Ang et al., 2002; Grandis et al., 1998). Upregulation of EGFR is
thought to influence important steps in tumor invasion and metastasis by enhancing cell
motility, regulating cytoskeletal changes, altering cell adhesion, and directing the
production of matrix-degrading proteolytic enzymes though downstream signaling
effector molecules such as phospholipase C gamma-1 (PLCy-1) and focal adhesion
kinase, in addition to promoting angiogenesis (Khazaie et al., 1993).

Enbate$ Motillity

Degradation ~f ECM

Figure 9: Signal transduction elements important to HNSCC invasion and
metastasis. (Howell and Grandis, 2005)

1.7.3. Matrix Metalloproteinases in Head and Neck Cancer
EGFR activation is known to increase activation of matrix metalloproteinase
(MMPs), in particular MMP-9 (Howell and Grandis, 2005). MMP-9 belongs to the MMP
family of zinc dependent endopeptidases, which have been associated with tumor cell
invasion, metastasis, and tumor-induced angiogenesis (Fridman et al., 2003). In addition,
the MMP family member pro-MMP-9, has been shown to be a key enzyme in tumor
progression playing a significant role in tumor cell invasion and in angiogenesis (Fridman
et al., 2003).

As a secreted MMP, pro-MMP-9 is released into the extracellular

environment by tumor and stroma cells, degrading both the ECM matrix and non-ECM

proteins, thus participating in events that are required for tumor cell migration and tumorinduced angiogenesis (Fridman et al., 2003).
An elevated EGFR level in HNSCC tumors correlates with the expression of
MMP-2, MMP-3, MMP-7, MMP-9, and MMP-10 (Howell and Grandis, 2005). MMP-2
and MMP-9 overexpression in tumor cells has been shown to correlate with invasion,
metastasis, and poor prognosis (Kawata et al., 2002; Ikebe et al., 1999; Hong et al.,
2000).

In addition, EGF has been shown to increase HNSCC invasion through a

basement membrane substitute and upregulate the expression of MMPs in HNSCC cell
lines, again with a significant upregulation of MMP-9 (0-Charoenrat et al., 2000).
Further, studies have demonstrated a failure of MMP upregulation, migration, and
invasion in HNSCC tumor cell lines on EGFR blockade (0-Charoenrat et al., 2000).

Figure 10: MMP cascade of zymogen activation involved in pro-MMP-9
activation. (Fridman et al., 2003)

Pro-MMP-9 can be activated by several different MMPs, including MMP-3
(Ogata et al., !992), MMP-2 (Fridman et al., 2003), and MMP13 (Knauper e? al., 1997.
This cascade of zymogen activation is initiated by MTl-MMP located at the cell
membrane and requires the activation of TIMP-2. With the generation of MMP-2 and
MMP-13, it can activate pro-MMP-9 (Fridman et al., 2003).

1.7.4. Phospholipase C Pamma (PLCy-1) and Head and Neck Cancer
PLCy-I is a ubiquitously expressed phosphoinositide-specific phospholipase that
is activated downstream of EGFR (Wells and Grandis, 2003). PLCy-1 is activated by
many growth factors including EGF and is required for cell motility (Howell and
Grandis, 2005). Since cell migration is critical for metastatic progression of tumor cells,
it is thought that the overexpression of PLCy-1 in HNSCC could contribute to invasion
and metastasis.

Interestingly, PLCy-1 regulates cell motility in response to growth

factors through the activation of actin-modifying proteins such as gelosin, and through
the hydrolysis of phosphoinositide (43 bisphosphate (PIP2) into diacylglycerol (DAG)
and inositol triphosphate (IP3), which are significant in the regulation of actin
cytoskeletal alterations and adhesionlde-adhesion mechanisms (Wells and Grandis,
2003).

Increased total and phosphorylated PLCy-1 has been reported in HNSCC tumors
compared with normal adjacent mucosa (Thomas et al., 2003). Furthermore, other
studies have shown that inhibition of PLCy-1 signaling significantly reduces in vitro
invasion through matrix barriers, suggesting that PLCy-1 plays a role in HNSCC invasion
and metastasis (Thomas SM et al., 2003). Therefore, the upregulation of PLCy-1 is one
downstream signal transducer that may mediate invasion and metastasis in HNSCC and
other epithelial tumors.

1.7.5. EGFR and Focal Adhesion Kinase
Focal Adhesion Kinase (FAK) is upregulated in several tumor types, including
HNSCC (Aronsohn et al., 2003). FAK is an intracellular nonreceptor tyrosine kinase,
which associates with integrins within cellular structures referred to as focal adhesions
and becomes phosphorylated and activated during integrin-mediated cell adhesion to
extracellular matrix (ECM) ligands (Howell and Grandis, 2005). Furthermore, FAK is an
important mediator of growth factor signaling, cell proliferation, cell survival, and cell
migration (McLean et al., 2005).
FAK expression and its activity are frequently correlated with malignant or
metastatic disease and poor patient prognosis (Recher et al., 2004; Schlaepfer et al.,
2004). Previous studies have shown an association between the enhanced expression and
phosphorylation of FAK and increased invasiveness and the metastatic ability in HNSCC
cell lines (Schneider, et al., 2002; Kornberg, 1998). In addition, gains in the FAK gene

copy number have been found in cells derived from head and neck cancer (Agochiya et
al., 1999).

Figure 11: Focal-adhesion kinase as a signal integrator. (McLean et al., 2005)

FAK carries out protein-protein interaction adaptor functions at the sites of cell
attachment to the ECM, which contributes to focal-adhesion and transmits adhesiondependent and growth factor-dependent signals into the cell interior (McLean et al.,
2005). FAK integrates signals from extracellular cues, including growth-factor receptors
and integrins, and from the upstream SRC-family kinases, to control and coordinate
adhesion dynarnicslcell migration with survival signaling (McLean et al., 2005).

Figure 12: Focal-adhesion kinase influences cell migration through additional
molecular signaling pathways. (McLean et al., 2005)

FAK mediated signaling events induce the expression of genes encoding MMPs
(McLean et al., 2003). As stated previously (section 1.7.3), once the MMPs are secreted
by the cell, they have the ability to mediate the breakdown of surrounding ECM
substrates and promote cell invasion (McLean et al., 2003).

1.7.6. EGFR and Angiogenesis
EGFR activation has been linked with an increase in angiogenesis and metastasis.
It has been proposed that EGFR-mediated signaling upregulates the expression of VEGF
and interleukin-8 (IL-8) by inducing downstream signaling pathways, which promote the
coactivation of transcription factors for IL-8 and VEGF expression, including nuclear
factor kappaI3 (NF-KB)and activator protein-1 (AP-1) (Bancroft et al., 2001). VEGF and
IL-8 are proangiogenic factors that are upregulated and coexpressed in HNSCC tumors,
and are associated with aggressive tumor growth and decreased survival rate (Eisma et
al., 1999; Bancroft et al., 2001). AP-1 is thought to activate the transcription of both

VEGF and IL-8, whereas, NF-KB activates IL-8 transcription as well as being important
for the expression of growth-regulated oncogene-1 (GRO-I), which is a neutrophil
chemoattractant whose increased expression has also been associated with HNSCC tumor
angiogenesis and metastasis (Bancroft et al., 2001; Shintani et al., 2004)

1.8. Aims of the Current Studs
1. To determine how vimentin expression differs in primary and metastatic HNSCC.
2. To determine if vimentin expression is modulated by the invasion-inducing
transforming growth factor P (TGF-P) and/or epidermal growth factor (EGF).
3. To determine if vimentin expression contributes to the invasive phenotype of
metastatic HNSCC cells.

4. To determine what mechanisms regulate vimentin gene transcription in metastatic
HNSCC.

2. Paper Introduction

In cancer progression, epithelial to mesenchymal transition (EMT) is associated
with tumor invasiveness, and intravasation and extravasations of metastatic cells
(reviewed in Thiery, 2002). For example, many invasive and/or metastatic tumors are
characterized by partial or complete EMT, in which the epithelial phenotype of tight
intercellular junctions and polarity across the epithelial layer is replaced by a more
mesenchymal phenotype with reduced cell-cell adhesions, altered shape, expression of
mesenchymal cellular markers, and enhanced cell motility (Ruiz and Gunthert, 1996;
Boyer et al., 2000; Wu et al., 2004). EMT is now being recognized as a hallmark of
tumor progression, characterizing invasive and metastatic carcinomas (Birchmeier et al.,
1996).
It has been suggested that the intermediate filament protein, vimentin, may be a
potential diagnostic marker for the initial progression of cells from a localized epithelial
lesion to become migratory, metastatic tumor cells (Gilles et al., 1996). There are
approximately fifty different types of intermediate filament protein that are categorized
into five subtypes, with vimentin belonging to type 111. Vimentin is normally expressed
in the cells of mesenchymal origin; therefore, it serves as an appropriate marker for the
transition of carcinoma cells from an epithelial to mesenchymal phenotype.

Vimentin displays a complex pattern of gene expression.

Eukaryotic gene

regulation studies suggest that multiple binding motifs are located within the human
vimentin promoter, some of which bind factors that enhance gene expression and others
that repress expression. These include: a TATA-box and several positive regulatory
elements such as eight GC-boxes (Rittling and Baserga, 1987); a PEA3 site (Chen et al.,
1996); an NF-KB site (Lilienbaum and Paulin, 1993); a A19 site (Salvetti et al., 1993); a
PS element (Wieczorek et al., 2000); two tandem AP-1 binding sites (Rittling et al.,
1989); a p-catenin site (Gilles et al., 2003); an antisilencer (ASE) element (Izmailova and
Zehner, 1999); and a proximal silencer (PS) element (Salvetti et al., 1993).
It has been shown that binding of the GC-box (at position -64 to -55) is critical
for the regulation of human vimentin gene expression (Izarnailova et al., 1999). The cJun protein synergizes with the activator protein spl to enhance vimentin gene expression
by binding to the GC-box1 (Wu et al., 2003). In addition to direct interaction with spl,
c J u n also binds to tandem AP-1 sites located upstream in the vimentin promoter in order
to activate vimentin gene expression (Wu et al., 2003). Interestingly, ZBP-89, a known
Kruppel-like zinc finger protein, is capable of interacting with spl and inhibiting the
activation of the vimentin promoter (Zhang et al., 2003). Furthermore, the PS silencer
element located between positions -319 and -261 binds ZBP-89, which represses gene
transcription (Wieczorek et al., 2000). An antisilencer element, ASE, located further
upstream (position -757) binds Stat3 and can overcome ZBP-89-dependent repression
(Wu Y., 2004). Interestingly, recent findings have shown that Stat3 is constitutively
activated in many metastatic tumors from a range of cell lineages (Bromberg et al., 1999;

Bromberg et al., 2001; Garcia et al., 2001; Zajchowski et al., 2001; Levy and Darnell,
2002).
EMT can be induced by a variety of growth factors, including EGF and TGF-P
(Miettinen et al., 1994; Bhowmick et al., 2001 ; Piek et al., 1999; Lu et al., 2003), and a
synergistic effect on EMT has been observed following treatment with a combination of
EGF and TGF-P (Grande et al., 2002). Interestingly, at the transcriptional level, EGF
and TGF-P activate different binding sites on the vimetin promoter, EGF targeting the
transcriptional binding protein, spl binding to GC-box and TGF-P targeting the tandem
AP-1 sites. In addition, EGF and TGF-P synergistically activate the transcriptional
binding protein, Stat3, which binds to the ASE site on the vimentin promoter.
Squamous cell carcinoma of the head and neck region (HNSCC) is the sixth most
common malignancy worldwide. HNSCC lesions are locally aggressive and frequently
undergo EMT, with metastasis to local and regional lymph nodes, which dramatically
decreases the likelihood of a good clinical outcome. Thus, prevention, early detection,
and the ability to prevent invasion and regional metastasis of the primary lesion are major
goals to combat this disease. In order to develop a model system in which to investigate
genetic, biochemical, and biological changes that occur during metastatic progression of
head and neck squamous cell carcinoma, we established HN4 cells from a primary tongue
tumor and HN12 cells from a synchronous lymph node metastasis and characterized their
behavior (Yeudall et al., 2005). Metastasis-derived HN12 cells are invasive in vitro and
tumorigenic in vivo, whereas HN4 cells are not. In addition, invasion of HN12 cells is
enhanced by epidermal growth factor (EGF; Yeudall et al., 2005) and by transforming

growth factor

P (TGF-P; Miyazaki et al., in press).

Comparing global gene expression

profiles of HN4 and HN12 cells revealed that vimentin gene expression was found to be
upregulated in metastasis-derived HN12 cells (Miyazaki et al., 2005).
Determining the mechanisms of vimentin gene regulation will contribute to our
.understanding of processes involved in EMT and might, potentially, provide insight into
factors controlling tumor cell invasiveness. In the present study, we have investigated
regulation of vimentin expression by EGF and TGF-P in metastatic HN12 cells, and the
contribution of vimentin overexpression to the cellular phenotype.

3. 'Materials and Methods

3.1 Cell,Cultures
HN4 cells were derived from a primary squarnous cell carcinoma of the head and
neck region, while HN12 was derived from a nodal metastasis in the same patient from
whom the HN4 cells originated. HNSCC cell lines were cultured in DMEM (Invitrogen
Corporation, NY) supplemented with 10% fetal bovine serum (FBS), and penicillin streptomycin (IOuglml) (Mediatech, Cellgro) in the presence of puromycin (lpglml) at
37°C in 90% air/lO% C02.

3.2 Plasrnids
Targeting sequences for vimentin-shRNA plasmids were designed using webbased software.
( h t t p : / l w w w . a m b i o n . c o r n / t e c h l i b / m i s c / s i ~ (Ambion,
)
Austin, TX) and the

sequences for senselantisense oligonucleotides are as follows: vimentin-shRNA sense, 5'-

GATCCGTAAGCACTAGCCACGACACTTTTCAAGAGAGTGTCGTGGCTAGTGC
TTATTCTTTTTTTCTAGAG-3'; antisense, 5'AATTCTCTAGAAAAAAAGAATAAGCACTAGCCACGACACTCTCTTGAAAAGT
GTCGTGGCTAGTGCTTAG-3'. Oligonucleotides for non-targeting controls were
sense, 5'-

GATCCGGCATGTACTAGCCTAAGCGTTTTCAAGAGACGCTTAGGCTAGTACA
TGCTTCTTTTTTTCTAGAG-3'; antisense, 5'AATTCTCTAGAAAAAAAGAAGCATGTACTAGCCTAAGCGTCTCTTGAAAACG
CTTAGGCTAGTACATGCG-3', respectively. Complimentary oligonucleotides were
diluted ta..l

Ow,mixed togethPs, boiled for 5 min in a water bath, and leftaxemight at

ambient temperature. Annealed oligonucleotides were ligated into the pSIREN-Retro-Q
retroviral vector (BD Biosciences Clontech, Palo Alto, CA) digested by BamHI and
EcoRI.

For chloramphenicol acetyltransferase (CAT) assays, 5'-deleted sequences
representing nucleotides -757/+72, -749/+72, -719/+72, or -216/+72 or point-mutated
sequences (-747/+72mAPl) of the human vimentin promoter were cloned upstream of
the CAT gene as described (Izmailova and Zehner, 1999; Izmailova et al., 2000;
Wieczorek et al., 2000; Wu et al., 2004). Promoter sequences are indicated in Figure 17
A and B.

3.3 Generation of Cell Lines that Stably Express shRNA Plasmids
HN12 cells containing vimentin shRNA or non-targeted control plasmids were
prepared as follows. HN12 cells were plated in 10cm tissue culture dishes at 60%
confluency, transfected with 3pg of plasmid DNA using TranslT Keratinocyte Reagent
(Mirus Bio Corporation, Madison, WI). 48h later, cells were selected in the presence of

lpglrnl puromycin.

Individual puromycin resistant colonies were isolated and

propagated.

3.4 Cell Transfection and CAT Assay
HN12 cells -were transfected using Amaxa Nucleofector Kit (Amaxa hc.,
Gaithersburg, MD) according to the manufacturer's recommended protocol. Cells were
plated (5 x lo5) in one well of a six-well plate and transfected with 1.5pg of plasmid
DNA and 0.5pg GFP in order to serve as an internal control for transfection efficiency.
The amount of each plasmid was optimized by transfecting different amounts of plasmid
DNA. After transfection (48h), cell lysates were prepared and CAT Elisa assays were
performed according to the provided protocol by Roche Diagnostic Corporation
(Indianapolis, IN). Alternately, after 24h transfection, cells were serum starved or treated
with the appropriate growth factor for 24h. Western blot analysis was performed using
GFP B-2 specific antibody (Santa Cruz Biotechnology, Santa Cruz, California).

3.5 Western Blot Analvsis
Cell extracts were prepared from HNSCC, parental vimentin shRNA, and control
transfected HN12 cell lines after 48h serum starvation or 24h serum starvation followed
by treatment with growth factors, EGF, TGF-P, or TGF-P and EGF for 24h. Cells were
washed and resuspended in 5 0 0 ~ of
1 ice-cold Lysis buffer (25 rnM HEPES, pH 7.5,0.3M
NaCl, 1.5mM MgC12, 0.2mM EDTA, 0.5mM DTT, 1% Triton X-100, 0.1% SDS, and

1rnM PMSF, and 0.4M NaCl). Cleared lysates were combined with SDS sample buffer,

denatured for 5 min at 100 "C, and resolved by 10% SDS-PAGE. Fractionated proteins
were electroblotted to PVDF membranes (Irnmobilon-P, Millipore Corporation, Bedford,
MA) overnight. The membranes were then blocked with 4% non fat dried milk in 0.03%
tween-TBS (T-TBS) for l h at room temperature, washed with 0.03% T-TBS three times,
and incubated with. anti-vimentin monoclonal antibody 1:1000 diluted in 4% non fat dried
milk for l h at room temperature. Membranes were then washed with 0.03% T-TBS three
times, incubated with horseradish peroxidase-conjugated (HRP) goat anti-mouse
monoclonal antibody 1:10000 diluted in blocking buffer for 1h at room temperature, and
washed four times in 0.03% T-TBS at room temperature. The specific antigen-antibody
interactions were detected using enhanced chemiluminescence (ECL Plus, Amersham
Biosciences, Piscataway, NJ).

3.6 Imrnunofluorescence
Cell lines (2 x lo5) were plated on coverslips in twelve-well plates and allowed to
attach for 24h. Cells were then serum starved for 48h, washed, and fixed with cold
methanol at -20°C for 20 min. Cells were washed with PBS for 5 min, and blocked in
5% BSA, 0.1% Triton-X 100 in PBS for l h at room temperature. Cells were incubated
with monoclonal anti-vimentin antibody (Sigma, St. Louis, MO) 1:250 diluted in
blocking buffer overnight at 4°C. The cells were then washed three times with PBS and
incubated with a FITC-conjugated anti-mouse antibody at 1:500 dilution in 5% BSA,
0.1% Triton-X 100 in PBS for l h at room temperature. Coverslips were mounted on a

microscope slide and viewed with a Zeiss Axiovent 200 inverted fluorescence
microscope.

3.7 Immunocytochemistry
Cell lines were plated on coverslips in twelve-well plates at 2 x 10~cells/well.
After 24h culture, cells were washed twice with PBS and serum starved for 48h or serum
starved for 24h and treated with EGF, TGF-P, or EGF and TGF-P for 24h. Cells were
washed, fixed with cold methanol at -20 OC for 20 rnin, washed with PBS for 5 min, and
blocked in 5% BSA, 0.1% Triton-X 100 in PBS for lh. Cells were incubated with antivimentin antibody as described above overnight at 4OC. Cells were then washed three
times with PBS and incubated with HRP-conjugated goat anti-mouse antibody (Cappel,
ICN Pharmaceuticals Inc., Aurora, OH) 1500 diluted in blocking buffer for l h at room
temperature and washed three times in PBS. The specific antigen-antibody interactions
were detected using a DAB staining kit (Vector Laboratories, Burlingame, CA) according
to the manufacturer's instruction. Coverslips were mounted on microscope slides and
viewed under an Olympus CK40 microscope.

3.8 Migration Assay
Subconfluent lOcm plates of cell lines were detached using HBSS / 5rnM EDTA /
25rnM Hepes pH 7.2 solution (Mediatech, Cellgro). The cells were then washed twice in
DMEM/O.l% BSA and resuspended in DMEM/O.l% BSA at a concentration of 1 x lo6
cells/rnl. Cells (1x10~)were added to the upper chamber of a 8pm pore size Transwell

(Corning Incorporated, Beverley, MA) and allowed to migrate for 6h. EGF (lOngIml)
-,

(Austral Biological, San Roman, CA) in DMEM/O.l% BSA was added to the lower
chamber of each well as a chemoattractant. The cells were then fixed in 100% methanol,
stained with 0.1% crystal violet in O.1M sodium borate pH 9, 2% EtOH overnight at
ambient temperature, and destained in ddH20. The non-migratory cells on the upper
surface of the membrane were removed with cotton swabs and mounted on a microscope
slide. Migrated cells were counted in five randomly selected high power fields per
membrane using an Olympus CK40 microscope.

3.9 Invasion Assay
Subconfluent lOcm plates of the HNSCC and vimentin stably transfected HN12
cell lines were detached using Cellstripper (Mediatech, Cellgro). The cells were then
resuspended in DMEM supplemented with 0.1% Bovine Serum Albumin (BSA) and
plated (2 x 1 0 ~ / 4 0 0 ~ 1in) the upper chamber of Matrigel-coated Transwell inserts (pore
size 12p.m) (Corning Incorporated, Beverley, MA).

In addition, 5 0 0 ~ 1of DMEM

supplemented with 0.1% BSA with lOng/ml EGF was added to the lower chamber of
each well. The cells were allowed to invade for 16h and then fixed with 0.5ml of 5%
glutaraldehyde in l x PBS for 10 min at ambient temperature and washed three times in
ddH20. The cells were stained with 0.1 % crystal violet in O.1M sodium borate pH 9, 2%
EtOH for 20 min at room temperature and then washed three times with ddH20. The
non-invading cells on the upper surface of the membrane were removed with cotton
swabs and membranes were mounted on microscope slides. Invading cells were counted

in five randomly selected high power fields per membrane using an Olympus CK40
microscope.

3.10 Proliferation Assay
Cell lines were trypsinized using 0.25% Trypsin-EDTA (Invitrogcn Corporation,

NY). The cells were then resuspended in complete growth medium containing lpglml
puromycin, counted, and plated 2 x 10' cells/well in twenty four-well plates. After 24h
of culture, triplicate wells were counted daily for eight consecutive days using a
hemacytometer.

3.11 qRT-PCR
To design the oligonucleotide primers for quantitative RT-PCR, we utilized the
Primerbank database
(http://pga.mgh.harvard.edu/primerbank/)

(Wang and Seed, 2003).

We

initially screened several set of primers by running PCR experiments to confirm that
these produced PCR products of the predicted size. The primers used were as follows:
Vimentin-qPCR

sense,

5'-CTCCTCCCCCTGTCACATAC-3';

antisense, 5'-TGATTGGCATCAGGACCGTTG-3'.

Vimentin-qPCR

Total RNA was extracted from

lOcm plates using 8ml of T r i a l reagent after washing with PBS twice, and 3pg of total
RNA was converted to cDNA using Superscript I11 (Invitrogen Corporation) according to
the manufacturer's instructions. Real-time quantitative PCR was performed using a
Lightcycler (Roche Diagnostics, Indianapolis, IN) with fluorescence signal detection

(SYBR green) after each cycle of amplification as previously described (Deb et al.,
2002). Product-specific amplification was confirmed by a melting curve analysis and
agarose gel electrophoresis analysis. Quantification was focused on the log-linear phase
of amplification above the baseline using the Lightcycler software. The calculated
cDNA copy number in each sample was derived from an extrapolated crossing point of a
mathematically derived line extending from the exponential phase of amplification in a
plot of fluorescence intensity (SYBR green) versus cycle number. For each reaction,
diluted amounts of known templates provided quantitative standard curve reactions from
which cDNA copy number could be determined. GAPDH was used as a housekeeping
gene to normalize the initial content of total cDNA in the samples.

4. Results

4.1 Upregulation of Vimentin in HN12 cells.
The derivation of the metastatic HN12 squamous carcinoma cell line and the nonmetastatic HN4 cell line has heerl described previously. When comparing the gene
expression pattern of these two cell lines using cDNA microarrays (Miyazaki et al.,
2005), we discovered overexpression of vimentin in HN12 cells. In order to confirm this
finding, we prepared total cellular RNA from serum-deprived HN4 and HN12 cells,
reverse-transcribed this and performed quantitative real-time PCR (qRT-PCR) on the
cDNA template using vimentin-specific primers. As shown in Fig. 13A (upper panel),
vimentin RNA is around 4-fold more abundant in HN12 cells compared to HN4. Further,
we confirmed vimentin overexpression in HN12 cells by western blot analysis of total
cellular protein lysates. Whereas vimentin was readily detectable in HN12 cell lysates,
no signal was obtained with HN4 lysates (Fig. 13A, lower panel).

In addition,

immunocytochemical staining (Fig. 13B) showed strong vimentin ubiquitous staining in
HN 12 cells, whereas this was absent in HN4 cells. Irnmunofluorescence microscopy (Fig
13C) revealed a dense network of vimentin filaments in the HN12 cells. These data
confirm that expression of vimentin is upregulated in cells at a later stage of tumor
progression and confirm the microarray findings.
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Figure 13A: Total RNA was extracted from subconfluent cultures, reverse-transcribed to
generate cDNA and subjected to real-time quantitative PCR as described in 'Materials
and Methods'. The relative expression ratio is defined as the expression levels of
vimentin to that of an internal standard, GAPDH. Assays were carried out in triplicate
and means+lSD are indicated. Parallel cultures, similarly treated, were used for western
blot analysis of vimentin expression. After 48h of serum deprivation, total cell protein
extracts were prepared as described in 'Materials and Methods' and analyzed for
vimentin expression (top panel). Levels of p-actin were determined as a loading control
(lower panel).

control

vimentin

Figure 13B: Analysis of vimentin expression in HN4 and HN12 cells using
immunocytochernistry. Cells were cultured on glass coverslips for 24h, serum deprived
for 48h, and fixed as described in 'Materials and Methods'. Cells were incubated with
anti-vimentin antibody (or mouse IgG as control) overnight and detected with HRPconjugated goat anti-mouse antibody and DAB.
microscope.

Images were viewed under a light
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Figure 13C: Analysis of vimentin expression in HN4 and HN12 cells using
imrnunofluorescence. Cells were cultured on glass coverslips for 24h, serum deprived for
48h, and fixed as described in 'Materials and Methods'. Cells were incubated with antivimentin antibody (or mouse IgG as control) overnight then incubated with a FITCconjugated anti-mouse antibody for l h and counterstained with DAPI. Images were
viewed using a fluorescence microscope.

4.2 EGF and TGF-fl Synergize to Increase Vimentin Expression.
Epidermal growth factor (EGF) and transforming growth factor

P

(TGF-P) are

thought to contribute to tumor metastasis through a number of mechanisms, including
enhanced cell migration and epithelial to mesenchymal transition (EMT), and have been
demonstrated to enhance migration and invasion of HN12 cells (Yeudall et al., 2005;
Miyazaki et al., in press). To determine whether either of these growth factors resulted in
upregulation of vimentin expression, we treated HN12 cells with EGF or TGF-P, or a
combination of both, then performed qRT-PCR using cDNA prepared from HN12 RNA
as a template. As shown in Fig. 14A (upper panel), vimentin RNA was increased by
around three-fold in TGF-P treated cells over basal expression levels, around five-fold
with the addition of EGF, and a synergistic seven-fold increase when cells were treated
with a combination of TGF-P and EGF. Interestingly in HN4 cells, we observed a
similar trend of vimentin upregulation but, even with the addition of both EGF and TGF-

p, expression was considerably lower than basal levels in HN12 cells.

As we had found that EGF and TGF-P elevated levels of vimentin RNA in HN12
cells, we sought to determine whether this was reflected by an increased abundance of
vimentin protein. Therefore, we treated cells with growth factors as before, prepared
total cellular protein extracts, and performed western blot analysis. Vimentin protein
expression was undetectable in HN4 cells by our assay (Fig. 14A, lower panel), even
with addition of growth factors. However, increased levels of vimentin protein were
detected in TGF-P and EGF-treated HN12 cells, concomitant with the previously

observed rise in vimentin RNA. Further, we analyzed vimentin expression in growth
factor-treated cells by irnrnunocytochernical staining.

HN12 cells displayed an

ubiquitous distribution pattern of vimentin throughout the cell, which was further
enhanced, with the addition of EGF and TGF-P (Fig 14B). Taken together, EGF and
TGF-P Ireatment result in increased vimentin RNA and protein levels in HN12 cells,
suggesting that both growth factors may play a role in EMT in this system. Further, EGF
and TGF-P stimulate expression of vimentin RNA in primary tumor-derived HN4 cells

with a trend similar to that seen in HN12 cells; however RNA levels are extremely low
and vimentin protein is undetectable.
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Figure 14A: Cells were cultured in the presence or absence of growth factors as indicated.
Total RNA was extracted from subconfluent cultures, reverse-transcribed to generate
cDNA, and subjected to quantitative real-time PCR as described in 'Materials and
Methods'. The relative expression ratio is defined as level of vimentin expression to that
of an internal standard, GAPDH. Assays were carried out in triplicate and means+lSD
are indicated. Parallel cultures, similarly treated, were used for western blot analysis of
vimentin expression as described in 'Materials and Methods' and as described in Figure 1.
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Figure 14B: Immunocytochernical analysis of vimentin expression in HN4 and HN12
cells with the addition of TGF-P and EGF. Cells were cultured on glass coverslips for
24h, then serum deprived for 48h or serum deprived for 24h and treated with EGF, TGFp, or EGF andfor TGF-P for 24h and then fixed as described in 'Materials and Methods'.
Cells were incubated with anti-vimentin antibody (or mouse IgG as control) overnight
and detected with HRP-conjugated goat anti-mouse antibody and DAB. Images were
viewed under a light microscope.

4.3 Tar~etedSuppression of Vimentin Expression.
In order to study the contribution of vimentin expression to the biological
properties of HN12 cells, we used RNA interference (RNAi) technology to reduce
vimentin levels. Thus, HN12 cells were stably transfected with a plasmid that directs
synthesis of a vimentin shRNA, or a non-targeting control (NTC) plasmid, and colonies
selected for resistance to puromycin and screened for vimentin expression by qRT PCR,
western blot analysis, and immunofluorescence.

As shown in Fig 15A, qRT-PCR

identified a ten-fold minimum decrease in vimentin expression in HNl2-shVim clones
compared to the HN12-NTC control cells.

In addition, this reduction of vimentin

expression was confirmed by imrnunofluorescence microscopy, which showed a
cytosolic distribution pattern of staining in the HN12-NTC clones and the absence of
staining in the HN 12-shVim clones (Fig 15B). Furthermore, vimentin expression was
undetectable by western blot analysis in either of the two HNl2-shVim clones compared
to the parental HN12 cell line and HNlZNTC clones (Fig. 15A). Taken together, these
data indicate that vimentin expression is substantially reduced in HN12-shVim clones
compared to non-targeting controls and, thus, may be suitable for investigating the
contribution of vimentin expression to the biological phenotype of metastatic HN12 cells.

Immunocytochemical staining demonstrated a significant increase of vimentin
expression in HN12-NTC compared to the HN12-shVim clones (Fig 15C). With the
addition of EGF and TGF-0, the expression pattern of vimentin in HN12-shVim cells
(Fig. 15C) is similar to the pattern seen in HN4 cells (Fig. 14B). Interestingly, there is a

slight increase in vimentin expression with the addition of either EGF or TGF-P
individually and an even greater increase with the addition of both growth factors
together. However, even with the addition of both growth factors to the HNl2-shVim
cell line, the expression of vimentin is considerably lower then the basal expression of
vimentin in HN12 and HN12-NTC cells. Further, we confirmed these results using
western blot analysis of total cellular protein lysates (Fig 15C).
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Figure 15A: Cells lines that stably express vimentin shRNA or non-targeting control
plasrnids were generated as described in 'Materials and Methods'.

Total RNA was

prepared from subconfluent cultures, reversed transcribed, and the resultant cDNA
subjected to quantitative real-time PCR as described above. The relative expression ratio
is defined as the expression level of vimentin to that of an internal standard, GAPDH.
Assays were carried out in triplicate and means+lSD are indicated. Western blot analysis
of vimentin expression (top panel) and actin as a control was carried out as described
above (lower panel).

NTC
Figure 15B: Cells were plated on glass coverslips for 24h, serum deprived for 48h and
then fixed as described in 'Materials and Methods'.

Cells were incubated with anti-

vimentin antibody (or mouse IgG as control) overnight followed by FITC-conjugated
goat anti-mouse antibody. Cells were counterstained with DAPI and detected using a
fluorescence microscope.
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Figure 15C: Cells containing vimentin shRNA or non-targeting control plasmids were
cultured on coverslips for 24h, serum starved for 48h, and fixed as described in
'Materials and Methods'. Cells were incubated with anti-vimentin antibody (or mouse

IgG as control) overnight then incubated with a HRP-conjugated anti-mouse antibody for
Ih. Images were viewed using a light microscope. Western blot analysis of vimentin
expression (top panel) and actin as a control was carried out on parallel cultures as
described above (lower panels).

4.4 Vimentin Overexpression is Important for Biological Properties of HN12 Cells.
Squamous carcinoma cells tend to grow more rapidly andlor fail to die at a normal
rate. In addition, these cells can also invade surrounding tissue and metastasize. Many
cells undergo EMT as a feature of tumor progression.

Thus, in order to determine

whether the mesenchymal cell marker, vimentin, contributes to the phenotype of HN12
cells, we first compared the proliferation rate in culture of HNl2-shVim and HN12-NTC
cells. Cells were seeded in quadruplicate in multi-well plates, then trypsinized and
counted over an eight day period. As is apparent from Fig. 16A, HNl2-shVim clones
exhibit a marked decrease in proliferation compared to the HN12-NTC cells, suggesting
that vimentin may contribute to cell growth. Next, we compared the contribution of
vimentin overexpression on the motility and invasiveness of HN12 cells using in vitro
assays. As shown in Fig. 16B, downregulation of vimentin expression in HN12-shVim
cell lines decreases migration in Transwell assays by four-fold in comparison to the
HNl2-NTC control clones. Furthermore, in vitro invasion through Matrigel is markedly
decreased in cells with lower expression of vimentin (Fig. 16C). Taken together, these
data indicate a crucial role for vimentin in the proliferation and invasion of metastatic
HN 12 squamous carcinoma cells.

Proliferation

time (days)

Figure 16A: Cells (2 x lo3 per well) were plated in triplicate in 24-well plates and
incubated under standard culture conditions as described in 'Materials and Methods'.
Cells were trypsinized and counted daily for eight consecutive days. Values shown are
meanskl SD.

Migration

0

Figure 16B: Cells from subconfluent cultures were detached in the absence of trypsin,
washed, and plated in Transwell chambers as described in 'Materials and Methods' with

EGF in the lower chamber to act as a chemoattractant. 6h later, migrated cells were
stained and counted in 10 random high power fields. Data shown represent means+lSD.

Invasion

Figure 16C: Cells from subconfluent cultures were detached in the absence of trypsin,
washed, and plated in Matrigel-coated Transwell chambers as described in 'Materials and
Methods'. 16h later, invading cells were stained and counted in 10 random high power
fields. Data shown represents means21 SD.

4.5 Regulation of Vimentin Promoter Activity in HN12 Cells by EGF and TGF-B.
How the vimentin gene is regulated is important for understanding the
relationship between gene expression and tumor progression which, based on our data
presented above, could ultimately contribute to controlling the invasiveness in some
tumors. Therefof?, we used vimentin promoter fragments, which begin at +72 and extend
to -261, -719, -749, and -757 to investigate which transcription factor binding sites
mediate upregulation of vimentin expression in HN12 cells. These promoter fragments
were cloned 5' to a CAT reporter gene and are shown in schematic form in Fig. 17A.
The vimentin promoter sequence is shown in Fig. 17B. Plasmids encoding vimentin
promoter-CAT sequences were transiently transfected into HN12 cells and CAT activity
measured by ELISA assay following serum withdrawal (Fig. 17C). The 261CAT
sequence containing the GC-boxl, PEA3 and NF-KB sites showed substantial activity
under conditions of growth factor withdrawal. This activity was much reduced in cells
transfected with the 719CAT plasmid, which contains two sites (PS and H4TF-1) that
bind the ZBP-89 repressor protein. Moderate restoration of activity was achieved with
the addition of two AP-1 binding sites in the promoter (749CAT), while further addition
of the ASE site (757CAT) further increased promoter activity (Fig. 17C). Taken together,
the data suggest that basal activity of the vimentin promoter in HN12 cells is mediated
through ASE and AP-1 sites, as well as one or more of the GC-boxl, PEA3 and NF-KB
sites. Furthermore, the data indicate that ZBP-89 repressor activity is high in these cells.

Next, we examined vimentin promoter activity in the presence of EGF and TGF-P
to determine the binding elements responsible for the increased vimentin expression
observed

by

qRT-PCR,

western

blot

analysis,

immunocytochemistry,

and

immunofluorescence. Using the 757CAT sequence, we found that treatment of cells with
either EGF or TGF-P stimulated promoter activity above that observed under conditions
of serum withdrawal, while the presence of both growth factors further elevated CAT
activity (Fig. 17D). In contrast, CAT activity in cells transfected with the 261CAT
sequences (containing the GC-box, PEA3 and NF-KB sites) was maximal in the presence
of EGF, which stimulated promoter activity by around 3-fold over basal conditions (Fig.
17E). Treatment of these cells with TGF-P did not produce any significant increase in
promoter activity. Surprisingly, addition of both growth factors simultaneously resulted
in lower activity than with EGF alone (Fig. 17E), suggesting that TGF-P may antagonize
the action of EGF on these promoter elements. However, in cells transfected with the
749CAT plasmid, TGF-P produced an increase in promoter activity of around 2.5-fold
over basal levels, whereas EGF had little effect (Fig. 17F). Similar to the results with the
261CAT sequences, addition of both growth factors failed to produce a synergistic effect,
implying that EGF antagonizes the TGF-P-mediated stimulation of the AP-1 sites. Taken
together, the data suggest that EGF-dependent pathways target binding elements in the
proximal vimentin promoter, while TGF-P is likely to act in an AP-1-dependent manner.
Furthermore, both growth factors appear to synergize by stimulating promoter activation
through the ASE site, suggesting involvement of Stat-dependent pathways in regulation
of vimentin expression in HN12 cells.
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Figure 17A: Regulatory elements [transcription factor binding sites] in the vimentin
promoter. The relative position of regulatory elements previously reported to be present
in the vimentin promoter is shown (top panel). 5'-deleted sequences or point-mutated
sequences of the human vimentin promoter were cloned upstream of the CAT reporter
gene as described in 'Materials and Methods'.

* indicates site of point mutation.
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Figure 17B: Nucleotide sequence of the vimentin promoter. Specific regulatory
elements are indicated (underline). Coding sequence is indicated (capitals).
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Figure 17C: HN12 cells were transfected with vimentin promoter fragments, which
begin at +72 and extend to -261, -719, -749, and -757 as described in 'Materials and
Methods'. 24h after transfection, cells were serum starved for 24h and then CAT activity
was determined by ELISA assay. The relative expression ratio is defined as the
expression level of vimentin to that of an internal standard, GFP. Values shown are
meanskl SD.

Figure 17D: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were
transfected with 757 CAT plasrnid.

Serum was withdrawn for 24h, then cells were

treated with the indicated growth factors for 24h after which CAT activity was
determined by ELISA assay. The relative expression ratio is defined as the expression
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD.

261CAT

Figure 17E: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were
transfected with 261 CAT plasmid. Serum was withdrawn for 24h, then cells were
treated with the indicated growth factors for 24h after which CAT activity was
determined by ELISA assay. The relative expression ratio is defined as the expression
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD.
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Figure 17F: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were
transfected with 749 CAT plasmid. Serum was withdrawn for 24h, then cells were
treated with the indicated growth factors for 24h after which CAT activity was
determined by ELISA assay. The relative expression ratio is defined as the expression
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD.

5. Discussion

5.1 Aims of Current Study
The aims of this study were to determine how vimentin expression differs in
primary and metastatic HNSCC cells; to determine if vimentin expression is modulated
by the invasion-inducing growth factors TGF-P and/or EGF; to determine if vimentin
expression contributes to the invasive phenotype of metastatic HNSCC cells; and to
determine what mechanisms regulate vimentin gene transcription in metastatic HNSCC.

5.2 HNSCC Model System
In order to develop a model system to study the nodal metastasis or oral squamous
cell carcinoma, the HN4 cell line was generated from a primary carcinoma of the tongue
and the HN12 cell line from a co-existing lymph node metastasis. Both of the cell lines
were found to have undergone identical inactivation of CDKN2A and P.53 genes, which
strongly suggests that the metastatic cells were the results of malignant progression of
cells from the primary lesion (Yeudall et al., 1994; Yeudall et al., 1997) and that they
were likely to have a similar genetic background. Previous studies have demonstrated
that P53 (Burns et al., 1994; Koch et al., 1994) and CDKN2A (Yeudall et al., 1994)
mutation found in the primary tumor are maintained during metastatic progression. HN4
cells were unable to form tumors in immunodeficient mice and HN12 cells were highly
tumorigenic in vivo,indicating that the HN12 cells are at a more advanced stage of tumor
progression (Yeudall et al., 2005).

5.3 Microarras Data
A high throughput analytical method, high density microarray technology, was
used to identify the genetic alterations that occur during metastatic progression or
primary oral squamous cell carcinoma (Miyazaki et al., 2005). The gene set documented
in this report, including ilimentin, overlap those identified from in vivo studies. which
suggest that the model has relevance for the study of HNSCC metastasis (Miyazaki et al.,
2005). The high basal levels of vimentin present in the metastatic cells, consistent with
their more mesenchymal appearance as well as the expression being elevated by both
EGF and TGF-P served as the foundation for the present study.
In addition, simultaneous exposure of both growth factors to HN12 cells resulted
in a higher level of vimentin expression than that found with either EGF or TGF-P alone
indicating some level of cooperatively between the EGF- and TGF-P-dependent signaling
pathways to the upregulation of vimentin expression (Miyazaki et al., in press). Here, we
investigate regulation of the vimentin promoter in the presence of EGF and TGF-P to
determine distinct promoter elements acted upon by these signaling pathways.

5.4 Vimentin as a Molecular Marker
Different intermediate filament proteins serve as markers for the identification of
normal, highly differentiated cells (Anguelov, 2000). Furthermore, intermediate filament
proteins are relied upon to help diagnosis tumor types, for example, vimentin is being
used as a marker for melanomas and keratin as a marker for adenocarcinomas (Anguelov,
2000). Molecular markers for malignancy, such as vimentin, are expected to become

reliable prognostic tools that will aid oncologists in fine-tuning their cancer management
strategies (Anguelov, 2000). This molecular diagnosis would allow physicians to stage
the patient's cancer more effectively and specifically tailor a treatment strategy that is
clinically and cost effective (Anguelov, 2000).

5.4.1 Upregulation of Vimentin in HN12 cells
In this study, vimentin RNA was found to be more abundant in HN12 cells
compared to HN4. Vimentin overexpression in HN12 cells was confirmed by western
blot analysis, immunocytochemical staining, and immunofluorescence microscopy.
Immunocytochemical staining showed strong vimentin ubiquitous staining in HN12 cells,
whereas this was absent in HN4 cells and immunofluorescence microscopy revealed a
dense network of vimentin filaments in the HN12 cells. These findings confirm that
expression of vimentin is upregulated in cells at a later stage of tumor progression
confirming the microarray findings. Concurrent with our results, other metastatic cell
lines have also been reported an upregulation in expression of the intermediate filament,
vimentin.
Using an androgen-independent model of prostate cancer, among the
differentially expressed genes between the two cells lines, LNCaP and CL1, vimentin
was overexpressed 20-fold in the C L l cells (Singh et al., 2003). The androgen-sensitive
LNCaP prostate cancer cell line is less invasive than hormone-insensitive cell lines
(Singh et al., 2003). CL1 is an aggressive hormone-insensitive LNCaP subline that was
derived by continuous culture in hormone-depleted medium (Singh et al., 2003).

Upregulation of vimentin expression was confirmed by northern and western blots and
visualized by immunofluorescence microscopy (Singh et al., 2003). In addition, these
data confirm the findings of previous studies in which the phenotypes of prostate cancer
cell line have been examined and LNCaP cells showed low levels of vimentin expression
in contrast to the ?igh expression seen in their more aggressive DU145 and PC3
counterparts (Nagle et al., 1987; Mitchell et al., 2000).

5.5 Vimentin Expression and Epithelial to Mesenchymal Transition
A major problem in cancer management is metastasis, the ability of the primary

tumor cells to migrate by the way of the blood or lymphatic vessels and to form tumors at
distant sites.

It has been reported that EMT facilitates the dissemination of single

carcinoma cells from the sites of primary tumors and is involved in the dedifferentiation
that is typical of metastatic carcinoma (Theiry, 2002). Originally, EMT was described in
the morphogenic remodelings during embryonic development (Hay, 1995; Boyer et al.,
1999). The acquisition of mesenchymal features by epithelial cells induced migration
during embryological processes (Savagner et al., 1994; Hay, 1995).
Now, we have come to appreciate the contribution of this phenomenon to both
pathological and normal processes where EMT can be diagnosed by the expression of
vimentin and the loss of epithelial cell-adhesion molecules (Savagner et al., 1994; Hay,
1995). EMT has been shown to occur in cultured mammary epithelial cells (Stoker et al.,
1987) in a bladder carcinoma cell line, NBT-11 (Boyer et al., 1989) and a prostate
carcinoma cell line (Singh et al., 2003). In culture, the definition of EMT is limited to

the escape of single cells from epithelial sheets, increased motility, and a modification of
the differentiation so that the migrating cells no longer express epithelial characteristics,
but require a mesenchymal phenotype (Boyer et al., 1989).
Using the bladder cell line, NBT-11, a study showed the mesenchymal phenotype
defined by the acquisition of vimentin, while the loss of the epithelial phenotype is
defined by the decline in keratin expression, in which a single marker defines the
phenotype (Petersen et al., 2001). It is this definition that has been adopted in the field of
breast cancer research (Petersen et al., 2001).
Thus, in a report studying EMT in human micrometastatic and primary breast
carcinoma cells, findings showed that all micrometastatic cancer cell lines displayed loss
of epithelial cytokeratins (CK8, CK18, and CK19) and ectopic expression of vimentin
commonly present in mesenchymal cells (Willipinski-Stapelfeldt et al., 2005).
Immunohistochernical analysis of breast cancer samples further showed that the loss of
cytokertain and ectopic vimentin expression were significantly associated with a higher
tumor grade and higher mitotic index. This study indicated that micrometastatic cancer
cells exhibit marked changes in the expression of cytoskeletal proteins indicative of EMT
and is associated with the aggressive behavior of breast cancer cells in vivo (WillipinskiStapelfeldt et al., 2005), and is consistent with our observations in HNSCC cells. This
increased expression of vimentin it the metastatic cell has been suggested as a critical
marker to distinguish 'true con~pleteEMT7 from cell scattering' or 'partial EMT'
(Grunert et al., 2003).

5.6 Vimentin Expression Suppressed in HN12 Cells
In order to study the contribution of vimentin expression to the biological
properties of HN12 cells, we used RNA interference (RNAi) technology to reduce
vimentin levels. Colonies were screened for vimentin expression by qRT PCR, western
blot analysi:,, and immunofluorescence, which showed a cytosolic distribution pattern of
staining in the HN12-NTC clones and the absence of staining in the HNl2-shVim clones.
HNl2-shVim clones show an efficient reduction compared to non-targeting controls and
thus were suitable for investigating the contribution of vimentin expression to the
biological phenotype of metastatic HN12 cells.

5.7 Vimentin Expression and Biological Properties
The ability of tumor cells to migrate and invade , which is interpreted clinically as
tumor aggressiveness, has been associated with changes in intermediate filaments
(Anguelov, 2000). The deregulation of intermediate filament gene expression in tumor
cells results in an intermediate filament phenotype, which is conducive to a higher
potential for invasion and migration (Anguelov, 2000). The observation that an altered
intermediate filament phenotype is associated with the ability of tumor cells to invade
adjacent tissues and organs and migrate in specific ways throughout the body could lead
to new strategies for cancer management.

5.7.1 Vimentin Expression is Important for the Biological Properties of HNSCC

The presence of regional metastasis in patients with HNSCC is a common adverse
event associated with poor prognosis and high mortality (Howell and Grandis, 2005).
Squamous carcinoma cells tend to grow more rapidly andlor fail to die at a normal rate.
In addition, these cells can also invade surrounding tissue and metastasize.
In order to determine whether the mesenchymal cell marker, vimentin, contributes
to the phenotype of HN12 cells, we first compared the proliferation rate in culture of
HN12-shVim and HN12-NTC cells. HNl2-shVim clones exhibit a marked decrease in
proliferation compared to the HN12-NTC cells, suggesting that vimentin contributes
positively to cell growth. In addition, in vitro invasion through Matrigel and migration
assays displayed markedly decrease in cells with lower expression of vimentin. These
findings indicate a crucial role for vimentin in the proliferation and invasion of metastatic
HN12 squamous carcinoma cells.
In accord with our HNSCC results, a study comparing the phenotype and
behavior of seven head and neck squamous cell carcinoma cell lines found that the
presence of the intermediate filament, vimentin coincided with the loss of anchorage
dependency and a malignant phenotype (Tomson et al., 1996).

5.7.2 Vimentin Expression and Biological Properties of Other Cell Lineages
After establishing that vimentin expression was only slightly detectable in LNCaP
cells and highly expressed in the faster-growing, more aggressive CLI subline, the study
mentioned previously (Section 5.4.2) assessed the contribution of vimentin to an invasive
phenotype (Singh et al., 2003). This study found that experimentally reducing the

expression of vimentin in the CLI cell line effectively abolished the invasive potential of
CL1 in the in vitro Matrigel invasion assays (Singh et al., 2003).
In addition, breast and cervical carcinoma models show the expression of
vimentin and the loss of E-Cadherin, an epithelial cell marker, to be associated with high
invasiv.- abilities (Gilles et al., 1997) Experiments conducted with a breast cancer cell
line showed that transient down-regulation of vimentin in MDA-MB-231 cells led to a
decrease in their migratory ability (Hendrix et al., 1997). The findings of another breast
cancer study revealed adriamycin-resistant MCF-7 cells expressing vimentin with
diminished keratin 19 expression to reduce desmosome and tight junction formation as
determined by reduced immunodetection of their components desmoplakins I and I1 and
zonula occludens (20)-1 (Sommers et al., 2002). Consistent with our data in HNSCC
cells, these studies confirm vimentin's

central role in the proliferation and

motility/invasiveness of advanced stage tumor cells.

5.8 Expression of the Vimentin Promoter in HN12 Cells
How the vimentin gene is regulated is important for understanding the
relationship between gene expression and tumor progression, and, based on our data
presented above, could ultimately contribute to controlling the invasiveness of some
tumors. For the most part, vimentin expression coincides with cellular growth and is cell
cycle regulated (Franke et al, 1979; Rittling and Baserga, 1987). We used vimentin
promoter fragments, which begin at +72 and extend to -261, -719, -749, and -757
relative to the translational start site to investigate which transcription factor binding sites

mediate upregulation of vimentin expression in HN12 cells.

The current model of

eukaryotic gene regulation suggests that many positive and negative acting factors
control the expression of the vimentin promoter (Wieczorek et al., 2000).
The 261CAT sequence containing the GC-box, PEA3 and NF-KB sites showed
substantial activity under conditions of growth factor withdrawal. It has been reported
that at least eight sequences, which match the GC-box consensus site were found within
the vimentin promoter (Rittling and Baserga, 1987). However, findings show that of
these multiple GC-boxes, expression of the vimentin promoter is dependent on GC-box1
located at position -64 which binds Spl (Izmailova et al., 1999). Mutation of the GCbox1 to a nonfunctional sequence results in little reporter gene expression despite the
addition of considerable upstream DNA demonstrating that this element is required for
regulated gene expression (Izmailova et al., 1999). Here, our findings demonstrate that
the transcriptional elements within 261CAT are important regulators for the activation of
vimentin expression with evidence specifically pointing to GC-box and NF-KB sites.
A recent article reveals that the activation of the transcription factor, NF-KB,

occurs in many human tumors and studies have shown that NF-KB can promote cell
proliferation and oncogenesis, possibly by protecting cells from apoptosis (Huber et al.,
2004). Little is known about whether NF-KB is involved in tumor progression including
EMT, which is a central process governing both morphogenesis and carcinoma
progression in multicellular organisms. However, in a combined in vitro/in vivo model of
mammary carcinogenesis, NF-KB was found to be essential in both the induction and
maintenance of EMT and for in vivo metastasis (Huber et al., 2004).

'

The activity of the vimentin promoter was much reduced in cells transfected with
the 719CAT plasmid, which contains two sites (PS and H4TF-1) that bind the ZBP-89
repressor protein. ZBP-89 is a zinc-finger, Kruppel-like protein, which is thought to be
ubiquitously expressed (Wu et al., 2004). ZBP-89 is a transcriptional repressor in the
case of vimentin (Wieczorek et al., 2000), epithelial neutrophil-activating peptide-78
(Keates et al., 2001), gastrin (Merchant et al., 1996), ornithine decarboxylase (Law et al.,
1998b), and bovine adrenodoxin (Law et al., 2000). However, for other genes such as
p21 (Hasegawa et al., 1999), a lymphocyte-specific protein tyrosine kinase (lck) (Yamada
et al., 2001), type 1 collagen (Hasegawa et al., 1997), and stromelysin (Ye et al., 1999), it
appears to activate gene expression (Wu et al., 2004). Furthermore, it has been suggested
that ZBP-89 is a negative regulator of cell growth as overexpression in two gastric tumor
cell lines (GH4 and AGS) inhibited cellular proliferation and led to cell cycle arrest of
GH4 cells in G1 (Remington et al., 1997).
Exactly, how ZBP-89 can function both as an activator and as a repressor of gene

I

I
expression is unknown. It has been proposed that, for some genes, ZBP-89 and Spl can

I

compete for binding to a GC-rich sequence (Law et al., 1998a). However, in the case of

I

the vimetin promoter, a separate PS element (at position -319 to -278) has been found,

I

which does not directly bind Spl (Wieczorek et al., 2000). Thus, in the vimentin gene,
ZBP-89 and Spl (or Sp3) bind to separate DNA elements and interact with each other
directly (Zhang et al., 2003). It has been proposed that this interaction accounts for the
dependence of vimentin gene activity on a functional GC-box1 and its associated factors
(Wieczorek et al., 2000).

Evident by our results using 719CAT is the apparent

interaction between ZBP-89 and PS and H4TF-1, transcriptional factors within the
promoter to repress the expression of vimentin.
Moderate restoration of activity was achieved with the addition of two AP 1
binding sites in the promoter (749CAT). Previous studies have implicated the activator
protein (API) transcription factors in tumor progression (Young et al., 1999). The APl
family of basic, leucine-zipper (bZIP) proteins is composed of heterodimers of Jun (cJun, JunB, JunD), Fos (cFos, FosB, Fral and Fra2) or ATF (ATF-1, ATF-2)/CREB, or
homodimers of JunIJun (Angel and Karin 1991; Rahmsdorf, 1996). Given the large
number of interactive partners, it is evident that the AP1 family can mediate the
expression of a wide variety of genes that could contribute to tumor progression (Wu et

al., 2003). The tandem AP1 sites with the vimentin promoter have been shown to be
important for the serum and TPA inducibility of the vimentin gene (Rittling et al., 1989),
as well as expression in vimentin-positive breast cancer cell lines (Sommers et al., 1994).
Here, the impacts of the AP1 sites on the vimentin promoter is evident not only with the
data demonstrating the increase of vimentin expression with the 749CAT plasmid
compared to 719CAT, but also the substantial decrease seen when the AP1 sites are
mutated in the 747mCAT.
It has been reported that, unlike many other proteins, c-Jun has the ability to
activate vimentin gene expression both by the classical method of c-Jun binding as either
a homodimer or heterodimer to its tandem APl sites as well as by an independent,
synergistic interaction with Spl, thereby enhancing its ability to recruit transcription
factors (Wu et al., 2003). In addition, it has been reported that c J u n synergizes with Spl

to enhance its subsequent binding to a GC-box element and only the leucine-zipper
region of c-Jun is required for this (Wu et al., 2003). This dual mechanism of action
could greatly affect levels of gene expression.
Addition of the ASE site (757CAT) further increased promoter activity.
Previously. it has been reported that the vimentin gene promoter contain an ASE site,
which is unlike the usual enhancer element in that it requires the presence of the PS
silencer element in cis to activate transcription fully (Stover and Zehner, 1992; Izmailova
and Zehner, 1999). It has been reported that the upstream ASE antisilencer site binds
Stat3 whereby its interaction with ZBP-89 can overcome repression and restore gene
expression (?Vu et al., 2004). Therefore Stat3, a proven oncogene, can interact with a
suggested growth suppressor, ZBP-89, to restore gene expression (Wu et al., 2004).
Thus, the interplay between Stat3 and ZBP-89, which could contribute to the activation
of vimentin gene expression as occurs in EMT (Gilles and Thompson, 1996) and is
crucial for controlling cellular growth by direct effects on gene expression.
Stats are a family of transcriptional activators, which play a central role in
signaling pathways involving cytokines, growth factors, or peptide hormones (Ihle, 1996;
Darnell, 1997; Horvath, 2000; Levy and Darnell, 2002). Activated receptors are proteinkinases of the JAK family, which phosphorylate Stats. Phosphorylated Stats form dimers
via their SH2 domains and rapidly translocate to the nucleus where they bind regulatory

DNA elements of target genes involved in cell proliferation, differentiation, apoptosis,
and development (Wu et al., 2004).

Stat3 is constitutively active in many tumors such as lymphomas, leukemia,
multiple myeloma, brain, breast, lung, head and neck, and prostate cancers (Bowman et
al., 2000), and the constitutively active form of Stat3 can mediate cellular transformation
(Bromberg et al., 1999). In addition, vimentin has been shown to be highly expressed in
these tumors (Busserrrtkers et al., 1992; Hsieh et al., 1995; Zajchowski et al., 2001).
Thus, a correlation between activated Stat3 and vimentin gene expression is indicated,
which coincides with the results of this present study.

In conclusion, the data suggest that basal activity of the vimentin promoter in
HN12 cells is mediated through ASE and API sites, as well as one or more of the GC
box, PEA3 and NF-lcB sites. Furthermore, the data indicate that ZBP-89 repressor
activity is high in these cells.

5.9 EGF and TGF-6 and Vimentin Expression
Epidermal growth factor (EGF) and transforming growth factor

P

(TGF-P) are

thought to contribute to tumor metastasis through a number of mechanisms, including
enhanced cell migration and EMT, and have been demonstrated to enhance migration and
invasion of HN12 cells (Yeudall et al., 2005; Miyazaki et al., in press). Vimentin RNA
was increased in TGF-P treated cells over basal expression levels, as well as with the
addition of EGF. In addition, a synergistic increase was evident when cells were treated
with a combination of TGF-P and EGF, suggesting that both growth factors play a role in
EMT in this system. In addition, western blot analysis demonstrated increased levels of

vimentin protein were detected in TGF-P and EGF-treated HN12 cells, concomitant with
the previously observed rise in vimentin RNA and immunocytochemical staining, HN12
cells displayed an ubiquitous distribution pattern of vimentin throughout the cell, which
was further enhanced with the addition of EGF and TGF-P.

5.10 EGF and TGF-B and the Virnentin Promoter
Next, we examined vimentin promoter activity in the presence of EGF and TGF-P
to determine the binding elements responsible for the increased vimentin expression
observed

by

qRT-PCR,

western

blot

analysis,

irnrnunocytochemistry,

and

immunofluorescence. Using the 757CAT sequence, we found that treatment of cells with
either EGF or TGF-0 stimulated promoter activity above that observed under conditions
of serum withdrawal, while the presence of both growth factors further elevated CAT
activity. In contrast, CAT activity in cells transfected with the 261CAT sequences
(containing the GC box, PEA3 and NFKB sites) was maximal in the presence of EGF,
which stimulated promoter activity. However, in cells transfected with the 749CAT
plasmid, TGF-P produced an increase in promoter activity over basal levels, whereas
EGF had little effect.
Taken together, the data suggest that EGF-dependent pathways target binding
elements in the proximal vimentin promoter, while TGF-P is likely to act in an AP1dependent manner. Furthermore, both growth factors appear to synergize by stimulating
promoter activation through the ASE site, suggesting involvement of Stat-dependent
pathways in regulation of vimentin expression in HN12 cells.

Here, our findings

demonstrate that the induction of vimentin expression with the addition of growth factors,
EGF and TGF-P occurs at the transcriptional level of the promoter targeting specific
transcriptional sites.

5 11 TGF-8 and Tumorigenesis

TGF-P is a multipotent cytokine that regulates a variety of cellular activities, such
as cell proliferation, differentiation, and extracellular matrix (ECM) formation (Liberati
et al., 1999). TGF-

P plays

a complex role in tumorigenesis since it has both tumor

suppressor and oncogenic activities (Akhurst and Derynck, 2001; Derynck et al., 2001;
Wakefield and Roberts, 2002). During the early stages of tumorigenesis, TGF- P, acts as
a tumor suppressor. It is suggested to be predominantly through its ability to induce
growth factor arrest and apoptosis in epithelial cells for which the majority of human
cancers derive (Nicolas and Hill, 2003). It is at the late stages when the pro-oncogenic
activities of TGF-

P dominate.

TGF-

P acts directly on the tumor cells to induce EMT,

and to increase motility, invasiveness and metastasis, and on the surrounding stroma to
suppress immune surveillance and increase angiogenesis (Akhurst and Derynck, 2001;
Derynck et al., 2001 ; Wakefield and Roberts, 2002).
TGF-P profoundly influences the differentiation of many cell types of
mesechymal origin, including preadipocytes (Ignotz and Masague, 1985; Choy et al.,
2000) osteoblasts (Centrella et al., 1994) and myoblasts (Olson, 1992). The identification
of genes transcriptionally regulated by TGF-P and the elucidation of the molecular
mechanisms responsible for this transcriptional regulalion will help define how TGF-P

exerts its cellular effects and its role in resulting physiological processes (Liberati et al.,
1999).
Interestingly, research studies have shown that it is the association of the Smad
complexes with transcription factors and transcriptional co-activators/co-repressors in the
nucleus that further regulate transcriptional control by TGF-P (Davies et al., 2005). The
receptor-associated Smads (R-Smads) interact directly with, and are phosphorylated by,
activated type I receptors of the TGF-P superfamily (Verrecchia et al., 2001).

5.12 TGF-D and AP1 Binding Sites
Numerous studies have characterized the differential expression of specific genes
in response to TGF-P, revealing a common link in the ability of TGF-P to regulate many
of these genes through the functions of the AP-1 family of transcription factors (Liberati
et al, 1999). The ability of TGF-P to induce the expression of several genes, including

PAI- 1, clusterin, monocyte chemoattractant protein- 1 (JEIMCP-I), type I collagen, and
TGF-P itself depends on specific APl DNA-binding sites in the promoter regions of
these genes (Keeton et al., 1991; Jin and Howe, 1997; Armendaruz-Borunda et al., 1994;
Kim et al., 1990; Takeshita et al., 1995; Mauviel et al., 1996). I t has also been shown
that expression of many APl proteins themselves is induced as an early response to TGF-

0 in a cell type-specific manner (Beauchamp et al., 1996; Blatti et al., 1992; Pertovaara et
al., 1989; Wong et al., 1999). These studies demonstrate a link between TGF-P signaling
and API in TGF-P regulated expression of various genes (Liberati et al., 1999).
Interestingly, components of the AP1 transcriptional complex were recognized early as

transcriptional targets of TGF-P signaling before the mechanisms of TGF-p transduction
were known (Pertovaara et al., 1989; Mauviel et al., 1998; Kim et al., 1990)

5.13 TGF-13 Induction via Smad Dependent and Independent Pathways

k has becn suggested that several genes, such as those encoding the plasminogen
activator inhibitor-1 (PAI-I), the a 2 chain of type I collagen (COLlA2), or the interstitial
collagnease (MMP-l), in which TGF-0 responsiveness was originally described as AP-1
dependent (Keeton et al., 1991; Chung et al., 1996; Mauviel et al., 1996) can also be
regulated by Smads, via either Smad-specific cis elements. It is known that Smad3
activation occurs in response to TGF-p, in which Smad3DNA interaction is detectable as
early as 10 minutes after TGF-P addition (Vindevoghel et al., 1998a). Recent findings
have demonstrated transcriptional responses depend on the structure of the target
promoter, whether they contain APl or Smad specific cis-elements (Verrecchia et al.,
2001).
It is now recognized that TGF-PI can activate mitogen-activated protein kinases
(MAPKs) (Hartsough and Mulder, 1995; Yamaguchi et al., 1995; Atfi et al., 1997;
Bhowmick et al., 2001b). The APl transcriptional complex is a primary target of a
number of MAPK pathways and it has been shown that APl components can interact
directly with Smad3 (Zhang et al., 1998, Peron et al., 2001; Verrechia et al., 2001). This
suggests that API may be central to crosstalk between Smad and MAPK pathways
(Davies et al., 2005).

There is convincing evidence for the involvement of MAPK signaling in TGF-PIinduced EMT (Ellenrieder et al., 2001; Zavadil et al., 2001; Bakin et al, 2002). A recent
study showed that TGF-pl-induced EMT involves Smad-dependent pathways (Davies et
al., 2005), which is in agreement with the limited number of studies using cells of human
origin (Ellenrieder et al., 2001; T i ~ net al., 2003). MAPKs function to enhance Smad
213-dependent transcription TGF-p 1-induced EMT (Davies et al., 2005). In conclusion,
MAPK and Smads pathways, together with the AP-1 complex mediate TGF-p 1-induced

EMT (Davies et al., 2005).
These research findings confirm our results, in which cells transfected with the
749CAT plasmid, TGF-P produced a substantial increase in promoter activity over basal
levels. This upregulation of the 749CAT vimentin promoter can be explained through
TGF-P interaction with the promoter tandem APl sites as there are a number of research
findings that provide strong evidence to support the role of Ap-1 in TGF-pl-induced
EMT.
Interestingly, research studies also show that the transcriptional factor NF-KB
functionally cooperates with Smad3 as well as the transcriptional factor protein, Spl,
which is found to functionally cooperate with Smad 21314 (Miyazono et al., 2001) These
research findings can be used to explain the upregulation of vimentin expression with the
addition of TGF-P to the 261CAT plasmid since both Smad 2 and 3 are activated by the
growth factor TGF-P.

5.14 EGFR Induction
The precise mechanisms by which growth factor-induced cell surface signals are
transmitted to the nucleus and ultimately result in cell division are partially understood.
In the response to ligands, EGFR dimerizes and becomes phosphorylated on multiple
tyrosine residues.

These phosphotyrosines, in turn, allow the activated receptor*

associate with other signaling proteins. Several EGFR signaling intermediates have been
described including ras/MAP kinase, PI-3-kinase, and PLCy.

5.15 EGF and spl bind in^ Protein
Despite the proven ability of spl to regulate the transcriptional activity of a
variety of genes involved in cell differentiation and proliferation (Merchant et al., 1995,
Li et al., 1995), little is known about its role in tumor growth and progression. High
levels of spl have been reported in gastric carcinomas (Kitadai et al., 1992) and a
coordinate overexpression of spl and lamin-yl was found in human hepatocellular
carcinomas (Lietard et al., 1997).
In a study using breast cancer models, western blot analysis with anti-Spl
antibody on nuclear extracts from seven malignant specimens and three breast lesions
conformed the presence of varying nuclear levels of spl proteins in the malignant tumors
and the absence of a detectable signal in benign breast lesions (Zannettii et al., 2000).
Promoter assays were studied and the binding data reflect Spl protein relative to the
levels assessed by western blot analysis of the same samples (Zannettii et al., 2000).

In addition , it has been previously shown for other genes, such as, gastrin
(Porchet et al., 1999) or apolipoprotein A-I (Zheng et al., 2001), that spl may participate
to EGF-mediated up-regulation of the target gene.

Using a lung cancer cell line,

researchers were able to show in MUC2 and MUCSAC, two target genes of EGFR
ligands in lung cancer. cells, that spl not only transactivated MUC2 and MlJC5AC
transcription but also participates in their up-regulation by EGF and TGF-a (Perrais et
al., 2002).
These studies confirm the substantial activation of 261CAT by EGF, indicating
that EGF targets the spl transcriptional binding protein within the vimentin promoter.
Interestingly, further studies might investigate the amount of spl protein in metastatic
HN12 cells to determine that not only is spl activated by EGF signaling pathway, but
there might also be an increased present amount of spl protein in the metastatic cell
similar to the breast cancer mentioned previously.

In conclusion, these studies help

define new therapeutic strategies in carcinomas in which one may want to efficiently and
selectively inhibit EGFR-signaling pathway to reduce or prevent metastasis.

5.16 Stat3 Protein and Metastasis
It has been shown that the Stat3 protein plays an important role in the growth and
survival of breast cancers in culture and in vivo (Gracia et al., 2001; Zajchowski et al.,
2001). Maximal Stat3 activation is thought to result from the cooperation of different
growth factors receptors, cytokine receptors, and nonreceptor tyrosine kinases (Wu et al.,
2004). Thus, constitutive activation of Stat3 is more predominant in highly aggressive,

metastatic breast cancers, and inhibiting Stat3 activation can block the malignant
progression of breast tumors (Bowman et al., 2000; Gracia et al., 2001). Established
breast cancer cell lines demonstrate constitutively active Stat3 homodimers (Sartor et al.,
1997).
EGF has been shown to be capable of activating Stats 1 and 3 in EGFRoverexpressing cells (Zhong et al., 1994; Leaman et al., 1996; Chin et al., 1996;
Nakamura et al., 1996), Stat activation in these cells has not been linked to proliferation
or transformation. However, recent studies show that Src-induced transformation of
fibroblasts results in Stat3-mediated gene expression (Turkson et al., 1998) and that Stat3
is constitutively activated in breast carcinoma cell lines but not in normal breast epithelial
cells (Gracia et al., 1997).

The results presented in these studies are the first

demonstration of growth inhibition after selective downmodulation of a Stat protein in
EGFR-overexpressiong cells.
These research findings confer with our results in which the EGF induced
activation of the 757CAT vimentin promoter, which contains the ASE transcriptional site
that is activated by the transcriptional protein, Stat3. In addition, 757CAT also displayed
induction with the addition of growth factor, TGF-P.
It has been proposed in other cell models the formation of a complex between
Stat3 and Smadl indicating that these two binding motifs may physically interact via an
adaptor molecule.

The CREB-binding protein (CBP)/p300 family of transcriptional

coactivators interact with various transcription factors, such as, APl, Myb, and nuclear
receptors altering there activity (Kamei et al., 1998). Interestingly, Smadl, 2, 3, and 4

associate with CBPlp300 family members (Nishihara et al., 1998; Janknecht et al., 1998).
This study showed the formation of a complex between Stat3 and Smadl, bridged by
p300, is involved in the cooperative signaling of LIF and BMP2 and the subsequent
induction of astrocytes from neural progenitors (Nakashima et al., 1999). In conclusion,
the transcriptiocnl cuactivator p300 physically interacts with Stat3 and Smadl, in which
the formation of a complex between Stat3 and Smadl, bridgedby p300, is involved in the
cooperative signaling of the pathway (Nakashima et al., 1999).
With Smadl being a downstream target of TGF-P and CBPlp300 family members
also associating with Smad2 and 3 provides strong evidence for the further increase in
induction of the 757CAT plasmid with the addition of TGF-P compared to EGF
stimulation alone.

Furthermore, this concept provides increasing evidence for the

synergistic effect found with the addition of both growth factors confirming Stat3 as the
target for induction by both EGF and TGF-P.

5.17 Conclusion
In conclusion, HNSCC remains the sixth most common malignancy worldwide
(Parkin et al., 1999; Landis et al., 1999). While primary lesion undergo hematogenous
spread only rarely, they are locally aggressive, and frequently metastasize to local and
regional lymph nodes, with lethal consequences (Yeudall et al., 2005). Therefore, it is
the prevention and early detection that are of great importance to reduce the incidence of,
and consequent morbidity from, HNSCC (Yeudall et al., 2005). One of the major goals
to combat this disease involves the ability to prevent invasion and regional metastasis of

the primary lesions. This requires a detailed understanding of the basic cellular biology
and biochemistry of invasion and metastasis in this cell system (Yeudall et ul., 2005).
With our findings, it can be suggested that particular transcription factors and the
signaling pathways involved in their activation should receive attention as potential
targets for the developments of novel anti-metastatic cancer treatments. .Fi.~turestudies
involve using a CHIP assay to confirm the findings of the transcriptional data. As well as
further evaluating our preliminary finding, which demonstrate a decrease of cytokertain
in the metastatic, HN12 cell line.

6. Future Experiments

6.1 Dcw_nregulation of Cvtokeratirr in 1-IN12 cells

Whereas vimentin is overexpressed in metastatic HN12 cells, an epithelial
specific intermediate filament, cytokeratin, is downregulated. Here, we show that HN12
cells demonstrate a downregulation of cytokeratin 13, 14, and 15 by western blot analysis
of total cellular protein lysates. After 48h of serum starvation, total cell protein extracts
were prepared as described in 'Materials and Methods' and analyzed for cytokeratin
expression (top panels). Levels of !3-actin were determined as a loading control (lower
panel). Anti-cytokeratin 13, 14, and 15 monoclonal antibodies were used (Waseem et al.,
1998; Waseem et al., 1999).

Whereas each cytokeratin was readily detectable in HN4 cell lysates, no signal
was obtained in HN12 lysates with cytokeratins 13 and 15 and diminished signal with
cytokeratin 14.

Furthermore, increased cytokeratin 13, 14, and 15 expression was

detectable by western blot analysis in two HN12-shVim clones compared to the parental
HN12 cell line and HN12-NTC clones. These data indicate that cytokeratin 13, 14, and
15 expression is downregulated at a later stage of tumor progression.
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